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 Our studies address early control points in the differentiation process that are 
necessary for expression as well as the maintenance of the adipocyte phenotype.  We 
have focused on the post-transcriptional regulation of mRNA metabolism by the RNA 
binding protein HuR.  Depending on the particular mRNA, HuR has been suggested to 
control polyadenylation, translocation to the cytosol, mRNA stability, and/or 
translational efficiency.  Using the 3T3-L1 preadipocyte cell line, we have demonstrated 
a critical role for HuR in the differentiation process by use of siRNA mediated 
suppression which resulted in an inhibition of differentiation.  We have identified 
several mRNAs that serve as HuR ligands early in the differentiation process, one of 
which is C/EBPβ, an important adipocyte transcription factor, whose expression is 
highly controlled and essential for proper acquisition of the adipocyte phenotype.  
Within minutes of induction of differentiation, HuR forms an mRNP complex with 
C/EBPβ mRNA in the nucleus followed by translocation to the cytoplasm.  HuR 
remains associated with C/EBPβ mRNA suggesting a role in mRNA stability and 
translation efficiency.  Our data suggest that formation of this complex in the nucleus 
serves as a regulator/attenuator of polyadenylation and that this interaction leads to a 
controlled metabolism of the C/EBPβ mRNA by determination of the quantity of 
message translocated to the cytosol and available for translation.  Additionally, our data 
have directed us toward the Zfp206 mRNA as an important HuR ligand whose 
regulation is predicted to be responsible for maintenance of the differentiation potential 
of the cells and whose expression is terminated as the cells express PPARγ and establish 
the adipocyte phenotype.  Our mechanistic analysis of these issues will identify novel 
control points in the initial stages of adipogenesis and thus fundamental to the 
pathological states of obesity and diabetes. 
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Chapter 1- Introduction and Literature Review 
The Epidemic Occurrence of Obesity 
 Obesity, world wide has reached epidemic proportions.  The World Health 
Organization reported in 2008, that over 400 million adults are obese (96).  In the United 
States alone, obesity affects up to one third of the adult population (about 60 million) 
and will claim more than 300,000 lives a year (3).  The number of obese Americans has 
continued to increase at an alarming rate and is the second leading cause of 
unnecessary deaths (3).   Obesity is projected to escalate to affect approximately 2.3 
billion people by 2015 (96).  This alarming rate of obesity heightens concern due to its 
implication with increased risk of many diseases and health conditions, such as, 
hypertension, coronary artery disease, dyslipidemias and even cancers (12).  Obesity 
results when energy input exceeds expenditure, giving rise to both hypertrophy and 
hyperplasia of adipocytes.  Hyperplasia is essential to the pathology of obesity through 
the enlistment and proliferation of preadipocytes followed by differentiation to 
adipocytes in the vascular stroma of adipose tissue, while hypertrophy simply refers to 
increased cell size  (25, 61).   
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Figure 1 - Hyperplasia and hypertrophy of adipocytes leads to the increase of adipose 
tissue associated with obesity (Adapted from Otto and Lane (61)). 
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Diabetes Associated with Obesity. 
 The prevalence of obesity among adult type II diabetics is approaching 90 
percent, which illustrates a strong correlation between obesity and diabetes type II (60).  
According to the World Health Organization, more than 180 million people worldwide 
suffer from diabetes (96).  The National Diabetes Information Clearinghouse estimates 
that in the United States $174 billion dollars are spent every year for the treatment of 
diabetes (58). 
 Type II diabetes, previously known as adult-onset diabetes, maturity-onset 
diabetes, or non-insulin dependent diabetes mellitus (NIDDM) is a disorder of 
carbohydrate metabolism that is characterized by persistent hyperglycemia.  Normal 
blood glucose levels range between 4 to 6 mmol/L, levels of glucose as seen in type II 
diabetes are in excess of 20 mmol/L.  The elevated glucose levels are a result of insulin 
resistance,  when normal or higher amounts of insulin are inadequate to produce an 
insulin response from fat  and muscle resulting in the diminish ability of these tissues to 
transport glucose across the cellular membrane, ultimately leading to type II diabetes 
(3).  
 In a lean healthy individual, small adipocytes store free fatty acids (FFA) as 
triacylglycerols (20), these triacylglycerols can then be mobilized to generate ATP via 
mitochondrial β-oxidation in the muscle during caloric deprivation (27). However, 
obesity alters adipose tissue metabolism resulting in the elevation of inflammatory 
mediators and the initial insulin resistance in skeletal muscle (27). During times of 
excess caloric intake an increase in TAG storage results in adipocyte hypertrophy (27).  
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Yet, in a non-diabetic individual this increase of TAG storage and β-oxidation in the 
muscle can be maintained and insulin resistance is prevented (27).  Conversely, 
excessive TAG overload in an overweight individual will result in adipocyte 
hypertrophy and increased secretion of monocyte chemoattractant protein-1 (MCP-1), 
which augments macrophage infiltration, adding to the pro-inflammatory state (27).  
Furthermore, the infiltrating macrophages secrete tumor-necrosis factor α (TNF-α), 
which in turn impairs TAG deposition and increases lipolysis (27).  The over abundance 
of ectopic TAG and FFA accumulation in the muscle disrupts mitochondrial oxidative 
phosphorylation and insulin-stimulated glucose transport, thus triggering insulin 
resistance (27).  
   It is necessary to understand the development and regulation of adipogenesis in 
order to manage the health implications of adipose tissue in obesity and diabetes (61).  
This review will address key components involved in the regulation of adipocyte 
differentiation and therefore provide insight into the development of obesity.  
 
Adipose Tissue, the Adipocyte and Obesity. 
 Practically all members of the animal kingdom, from C. elegans to Homo 
sapiens, have evolved means to store energy during excess caloric intake for future 
need (25).  In most species, fat is stored as triacylglycerol in the adipocyte and can be 
mobilized via lipolysis, resulting in secretion of free fatty acids and glycerol  (1).  In 
mammals, two distinct types of adipose  tissue have been classified: white adipose 
tissue(36), the primary site of energy storage, and brown adipose tissue which is 
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specialized to metabolize fatty acids and generate heat (32, 62).  White adipose tissue is 
distributed throughout the body in multiple depots, both subcutaneously (buttocks, 
thighs, and abdomen) and intra-abdominally (omentum, intestines, and perirenal area) 
(25, 87).  It is important to note that mature adipocytes are not the only cell type that 
constitutes the adipose organ; fibroblasts, endothelial cells and macrophages compose 
up to 50% of the total cellular content (87).  
 Adipose tissue is important not only because it is the body’s largest energy 
reservoir but it is now recognized as playing a major role in the regulation of 
metabolism and homeostasis through paracrine and endocrine functions (27, 61).  
Adipocytes and adipose tissue produce a diverse range of secreted factors termed 
adipokines or adipocytokines, that effect numerous functions, including glucose 
metabolism (e.g. adiponectin, resistin), feeding behavior (leptin), lipid metabolism (e.g. 
cholesteryl ester transfer protein, CETP), inflammation (e.g. TNFα, IL-6), coagulation 
(PAI-1), blood pressure (e.g. angiotensinogen, angiotensin II) , as well as, influencing 
reproductive functions, insulin sensitivity and insulin secretion (28, 61).  
 A key adipocytokine in this system is leptin, a 16 kDa secreted hormone that acts 
on the hypothalamus of the brain inducing satiety. Leptin informs the brain on the 
status of body fat abundance that results in an alteration in feeding behavior (99).  
Leptin was first discovered in 1994, as the product of the Ob gene in genetically obese 
(ob/ob) mice (87).  Plasma levels of leptin are generally proportional to adipose tissue 
mass, in a lean individual circulating levels are between 5-15 ng/ml (99).  Increased 
expression of leptin is induced by overfeeding, insulin, glucocorticoids, and cytokines. 
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Leptin expression is decreased by fasting, testosterone, thyroid hormone and exposure 
to cold temperatures (99).  To induce satiety, leptin binds to leptin receptors (Ob-R) in 
the basomedial hypothalamus.  Neurons in this region are stimulated to synthesize 
proopiomelanocortin (POMC), which is cleaved to produce α-melanocyte stimulating 
hormone (αMSH), which then binds downstream melanocortin (MC) receptors.  
Signaling through MC-3 and MC-4 receptors limits food intake and body fat mass (73).  
Leptin also signals through another hypothalamic signaling pathway that decreases 
food intake by inhibiting neuropeptide Y (NPY) production.  NPY, the most potent 
orexigenic substance in our body, stimulates food intake and decreases energy 
expenditure while inducing lipogenic enzymes in liver and adipose tissue (73).  
 Adipose tissue also secretes cytokines like TNF-α and peptides such as 
angiotensinogen. TNF-α is involved in inflammation, immune modulation and type II 
diabetes (as described previously), while angiotensinogen is implicated in wound 
healing, vascular remodeling, and regulation of blood pressure (27, 61).  
 Deregulation of adipose cells can cause obesity, type II diabetes, cardiovascular 
disease, hypertension, sleep apnea and muscular skeletal problems (1, 61).  Obesity 
develops when energy intake persistently exceeds energy expenditure.  Obesity is 
associated with marked changes in adipocyte gene expression that affects many 
pathways.  Equally important to the development of obesity is the alteration of the 
secretory functions and the disregulated cellular homeostasis associated with larger 
adipocytes due to hypertrophy (67).  Dysregulation of adipokine expression is now 
thought to be one of the key events in the pathogenesis of this metabolic disease (89).  
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There is a great need to understand the molecular mechanisms regulating this dynamic 
cell type and its involvement in disease states.  The adipocyte can no longer be 
considered a inert cell whose exclusive function is to store lipids due to the emergence 
of new roles in diverse pathways of physiological and pathological processes (55).   
 
Adipose Development and Regulation 
 Adipose tissue, bone and muscle originate from a multipotent stem cell 
population of mesodermal origin (25, 62).  Mesodermal formation begins with the 
migration of cells during gastrulation, these cells form an additional germ layer 
between the primitive endoderm and ectoderm cell layers of the developing embryo 
(25).  A great deal of our understanding of these events comes from studies using the 
C3H10T1/2, a multipotent stem cell line, isolated from 14 to 17 day C3H mouse 
embryos.  The current model for stem cell commitment suggests that a common 
mesoderm/mesenchymal stem cell (MSC) gives rise to adipoblasts, osteoblasts, 
chondrocytes, myoblasts, and connective tissue in response to the appropriate 
developmental cues (25, 62).  A MSC gives rise to an early precursor of the adipose cell 
lineage, the adipoblast, which then develops into committed white and brown 
preadipocytes in the vascular stroma (25, 61).  One of these developmental cues 
necessary for this transition has been suggested to be bone morphogenetic protein-2 
(BMP2) and BMP4, members of the transforming growth factor β superfamily, which 
are cytokines that have been shown to induce commitment of C3H10T1/2 pluripotent 
stem cells to the adipocyte lineage (34, 80).   
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 Adipogenesis is the processes by which preadipocytes differentiate into mature 
fat cells.  This progression includes the expression of genes needed for the alteration of 
cell shape, glucose metabolism, the acquisition of insulin sensitivity, expression and 
secreting of adipogenic products, and the appearance of cytoplasmic lipid droplets (55).  
This shift in gene expression is regulated by a cascade of transcription factors that 
interact in an intricate manner to control expression of hundreds of adipogenic genes.  
There are two families of transcription factors critical to the process that have been 
studied at length, they include the CCAAT enhancer-binding proteins (C/EBPs) and 
the peroxisome proliferator-activated receptor (PPAR) family of nuclear hormone 
receptors, Fig 2 (29, 55).  
 The C/EBPs belong to a large family of basic-leucine zipper (bZIP) 
transcription factors. The general structure of the C/EBPs includes a C-terminal leucine 
zipper domain that allows dimmer formation, and a basic domain that binds to a 
consensus sequence on DNA.  Six members of this family have been characterized, α, β, 
δ, γ, ε, and ζ; they are all capable of forming hetero- and homodimers that will bind to 
promoters/enhancers of different genes to alter expression.  C/EBPα, β and δ are three 
family members that have been extensively studied due to their important involvement 
in the regulation of adipogenesis (29, 55, 70).  Freytag and colleagues demonstrated that 
ectopic expression of C/EBPα in a variety of fibroblastic cells could induce 
adipogenesis (20).  Furthermore, total ablation of C/EBPα (except liver) in knockout 
mice demonstrated that C/EBPα is required for white adipose tissue formation, and not 
brown adipose tissue formation (50).  Ectopic expression of C/EBPβ alone induces 
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adipogenesis in nonadipogenic NIH 3T3 fibroblasts (19). McKnight and colleagues 
agree that C/EBPδ alone possesses minimal adipogenic activity, but together with 
C/EBPβ, play important roles in the induction of C/EBPα (11).  
 The PPARs represent a subset of the nuclear hormone receptor superfamily 
whose transcriptional activity is altered by ligand-receptor interactions (55).  The PPAR 
family members include PPARα, PPARγ, and PPARδ, which bind to the peroxisome 
proliferator response elements on DNA.  PPARγ has been implicated as the only PPAR 
family member to play a major role in adipogenesis.  Studies have shown that ectopic 
expression of PPARγ in nonadipogenic mouse fibroblasts can initiate the entire 
adipogenic program, giving rise to mature adipocytes (86).  PPARγ is expressed in two 
isoforms generated by alternative promoter usage of the same gene, PPARγ1 and 
PPARγ2 (19). These isoforms gives rise to four distinct mRNAs, pparγ1-4.  All four 
mRNAs encode the PPARγ1 polypeptide, while pparγ2 mRNA encodes the PPARγ2 
polypeptide, which is identical to PPARγ1 with the exception of an additional 30 amino 
acids at the N-terminus (19).  PPARγ1 is expressed in many tissues, however PPARγ2 
expression is almost exclusively found in adipose tissue (19).  Both PPARγ1 and 
PPARγ2 isoforms form heterodimers with retinoid X receptor (RXR) then bind to 
promoters/enhancers of target genes (90).    
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Figure 2 - Transcription factor pathway that mediates adipocyte differentiation 
(Adapted from Morrison and Farmer (55) ).  C/EBPβ and C/EBPδ transcription factors 
transactivate expression of PPARγ and C/EBPα. PPARγ and C/EBPα co-regulate each 
others expression and together transactivate the expression of the genes responsible for 
the acquisition of the adipocyte phenotype.  
 
  
C/EBPβ
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The PPARγ-RXR complex binds ligands, such as, 9-cis-retinoic acid, 15d-PGJ2 or fatty 
acids in the C-terminal hydrophobic pocket (29, 72, 90).  Recent work by Spiegelman 
and Walkey, suggest that ligand binding is not a requirement for PPARγ function in the 
adipose differentiation process (90).  
 The regulation of gene expression is important for the acquisition of the 
adipocyte phenotype and depends on a cooperative interplay and transactivation 
between the C/EBPs and PPARγ transcription factors.  In knockout mice, Tanaka et al 
demonstrated that mice lacking both C/EBPβ and -δ were defective in the ability to 
generate adipose tissue (75).  McKnight and associates showed that C/EBPβ and -δ are 
expressed earlier than C/EBPα during adipogenesis and are responsible for the 
expression C/EBPα (19).  It was hypothesized that C/EBPβ and δ simultaneously 
controlled both PPARγ and C/EBPα (19).  Others hypothesized that C/EBPβ induces 
C/EBPα and together those two factors regulated PPARγ.  Recently, studies with 
retroviral expression of C/EBPβ in ppar-/- MEFs, showed that C/EBPβ was incapable 
of stimulating C/EBPα expression in the absence of active PPARγ (107).  Furthermore, 
ectopic expression of  C/EBPβ in Swiss fibroblasts was able to induce expression of 
PPARγ but was unable to induce C/EBPα expression to any significant degree in the 
absence of a potent PPARγ ligand (19).  Therefore, as shown in figure 3, the cascade of 
transcription factors of adipogenesis involves the induction of C/EBPβ and C/EBPδ, 
which then mediates the expression of PPARγ (107).  PPARγ along with C/EBPβ and δ 
then activates C/EBPα by binding to C/EBP consensus sequences in the promoter 
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region.  Once PPARγ and C/EBPα are activated, they can then maintain each others 
gene expression through cross-regulation, even after C/EBPβ and C/EBPδ expression 
has diminished (55, 66).  The co-expression of PPARγ and C/EBPα leads to the 
expression of adipogenic specific genes.  
 An additional transcription factor family known as the sterol regulatory element 
binding proteins (SREBPs) is also recognized to play a role in the modulation of 
transcription of numerous genes encoding proteins essential in both cholesterol and 
fatty acid metabolism (55).  The SREBP family consists of three members, SREBP-1a, -1c, 
and -2, which contain two transmembrane domains that anchor the protein to the 
endoplasmic reticulum.  When sterol levels are low, two proteolyic events occur and 
cause the release of the N-terminal fragments of the SREBP protein into the cytoplasm.  
The SREBP fragments then translocate to the nucleus where they can bind to promoters 
of target genes.  SREBP-1a and -1c have been primarily implicated in the regulation of 
fatty acid biosynthesis and SREBP-2 regulates cholesterol metabolism (55).  Studies with 
SREBP1c in regulating adipogenesis demonstrated that its expression significantly 
augmented the 3T3-L1 adipocytes ability to respond to insulin.  Moreover, ectopic 
expression of a dominate-negative SREBP1c was shown to inhibit differentiation.  
Others have shown that SREBP1c is linked to the induction of PPARγ1 expression 
through SREBP binding sites in the promoter regions responsible for  pparγ1 and γ3 
transcription (19).  Many additional transcription factors are components to this 
complex cascade of factors that are responsible for induction of adipogenesis, the factors 
outlined above are considered the main players.    
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3T3-L1 preadipocyte: A model for the mechanism of adipogenesis 
 Adipogenesis follows a highly ordered temporal sequence of events.  The 
knowledge of these events and the factors involved have been greatly enhanced by the 
development of cell lines that differentiate from fibroblastic like cells into mature 
adipocytes (55).  The 3T3-L1 preadipocyte cell line derived from Swiss 3T3 cells, has 
been extensively characterized and is one of the most notable of these cell lines that are 
committed to the adipocyte lineage (61).  In the first steps of adipogenesis in vitro, the 
proliferating 3T3-L1 preadipocytes exhibit contact inhibition of growth.  These growth-
arrested cells reenter the cell cycle after addition of the differentiation inducers (MDI), a 
combination of isobutylmethylxanthine (M, a cAMP phosphodiesterase inhibitor), 
dexamethasone (D, a glucocorticoid), insulin (I, which acts through the insulin-like 
growth factor-1 receptor), and fetal bovine serum (FBS); the cells then undergo several 
rounds of cell division referred to as mitotic clonal expansion (29, 65, 72).  Mitotic clonal 
expansion mimics the increase in cell number (hyperplasia) observed in obesity (19).  
Recent evidence, demonstrating that inhibition of proliferation with drugs that block 
cell cycle at S phase prevent adipogenesis, is consistent with MCE being required for 
terminal adipocyte differentiation (19).  It is believed that re-organization of chromatin 
during mitosis is needed to facilitate accessibility of cis-elements to trans-factors 
essential for transcription of genes that give rise to the acquisition of the adipocyte 
phenotype (19, 61).  In 3T3-L1 preadipocytes, the onset of MCE is characterized by 
changes in expression of cyclin E/A, cdk2 and turnover of cyclin-depended kinase 
inhibitors p18, p21 and p27 (61).  As the cells traverse the G1/S check point, the 
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initiation of the transcription factor signaling cascade, as shown in Fig. 2, is started 
when C/EBPβ acquires DNA-binding activity (81).  Figure 3, displays the protein levels 
of the three members of the C/EBP family involved in the differentiation program. 
Although it has been shown that C/EBPβ gene is rapidly expressed after induction of 
differentiation with protein found in the nucleus within 2 hours, DNA-binding activity 
is not acquired until dual phosphorylation by mitogen-activated protein kinase (MAPK) 
and  glycogen synthase kinase 3β (GSK3β) that occurs within 14 hrs (76, 101).  This 
event triggers the transcription factor cascade as described in the previous section.  
Terminal differentiation is maintained, at least in part, through the expression of 
C/EBPα and PPARγ.  The expression of C/EBPα has been shown to be antimitotic and 
is thought to be responsible for termination of MCE as the cells exit the cell cycle (61). 
This anti-mitotic activity elicited by C/EBPα is through direct interaction with cyclin-
dependent inhibitor p21 and cyclin-dependent kinase cdk2 to directly inhibit the cdk 
enzymatic activity required for cell cycle progression (30).  Importantly, it is pertinent to 
note that C/EBPβ expression is essential for the movement of the cells from a quiescent 
stage through MCE and terminal differentiation.  
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Figure 3 - CCAAT/ enhancer binding protein (C/EBP) family members involved in 
adipogenesis. Basal level C/EBPβ protein is found -4 days prior to cell confluence. 
Together C/EBPβ and C/EBPδ protein levels rise after treatment with differentiation 
inducers. C/EBPα protein levels dramatically rise 2 days post induction of 
differentiation and remain at 100% activity. As C/EBPα reaches 100% activity C/EBPβ 
protein levels begin to steadily decline and lipogenic enzyme gene expression increases. 
C/EBPδ protein levels dramatically decrease after induction of C/EBPα expression. 
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CCAAT/ Enhancer Binding Protein β (C/EBPβ) mRNA 
 C/EBPβ is our transcription factor of interest, as there is considerable data to 
support its role as a key regulator of adipogenesis (79, 81, 102).  C/EBPβ is encoded by 
an intronless gene and its mRNA produces several protein isoforms due to alternative 
translation initiation sites (4, 68).  These in frame AUG start codons produce three N-
terminal truncated isoforms corresponding to protein species of, 38, 35, and 20 kDa (4, 
68).  The p35 protein, the full length transcription factor, is referred to as LAP (liver-
enriched transcriptional activator protein), which is a potent transactivator of gene 
expression.  The p38 isoform (LAP*) is also a full length transcription factor but is not 
produced as frequently as p35. The p20 protein is referred to as LIP (liver inhibitory 
protein), which lacks the amino terminal transactivation domain but contains the bZIP 
domain (29, 79).  LIP can act as a dominate-negative repressor of LAP activity and can 
actually block adipogenesis of preadipocytes in culture if the ratio of LAP to LIP is < 1 
(29).   
 The molecular mechanisms that regulate the selection of alternative 
translational start sties of C/EBPβ are not well understood. Three mechanisms have 
been proposed.  First, selection is controlled by an out of frame upstream open reading 
frame (uORF) in the 5’ untranslated region (UTR) (29, 79).  Xiong et al (98) demonstrated 
that multiple C/EBPβ isoforms are produced by alternative translation initiation at the 
multiple AUG start sites, and demonstrated a role for the uORF in the regulation of 
alternative translation initiation by a ribosomal scanning mechanism.  Work by 
Calkhoven et al (10) suggests that the LAP to LIP ratio is controlled by the 5’ uORF and 
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the availability/activity of translation initiation factors eIF2α and eIF4E. They 
demonstrated using COS-1 cells transfected with C/EBPβ constructs, that 
overexpression of eIF2α and eIF4E enhanced expression of the truncated isoform (59).  
Secondly, Welm et al have proposed an alternate mechanism involving a proteolytic 
cleavage of LAP to generate LIP, in vivo and in vitro (5, 95).  Finally, data by Timchenko 
et al, suggests that translation of LIP and LAP is controlled by CUG repeat binding 
protein -1 (CUGBP1), which binds to the 5’ untranslated region of the C/EBPβ mRNA 
and regulates a leaky ribosomal scanning mechanism (83, 84).  Although the role of 
CUGBP1 has been studied in myogenesis, nothing is known about the role it plays in 
preadipocyte differentiation (4).  
 
Post-Transcriptional Gene Regulation and RNA Binding Proteins. 
 In recent years post-transcriptional processes have gained recognition as key 
points of precise gene regulation.  Post-transcriptional regulation is an adaptive 
mechanism that allows the cell to adjust gene expression according to environmental 
changes and physiological processes such as, stress, proliferation, and differentiation 
(14, 16, 31).  Steps in the post-transcriptional mRNA processing, including splicing, 
polyadenylation, stability, editing, localization, decay and translation, can provide 
points of regulation to modulate changes in protein levels of a specific gene (31, 63).  
 Post-transcriptional regulation is dependent on the activity of a variety of trans-
acting factors, known as RNA-binding proteins (RBPs).  It has been estimated that there 
are more than one thousand RBPs in the human genome.  From the beginning of a pre-
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mRNA molecule’s journey in the nucleus to the ribosome in the cytosol, RBPs are a 
constant accessory.  RBPs bind to cis-elements (protein binding sites) which are 
frequently present within the 3’ untranslated region (UTR) of the messenger RNA but 
can also be located in the 5’UTR, in introns, and even in coding sequences.  The 3’UTR 
of mRNA is widely known for bearing sequence motifs that determine the rate of 
mRNA decay.  The most commonly studied group of destabilizing motifs are the  
adenine- and uridine-rich elements (AREs), which are characterized by a highly 
conserved AUUUA pentamer sequence (16, 63).  Many mRNAs subject to rapid 
response to cell environmental stimuli, such as, growth-response genes, cytokines and 
proto-oncogenes, contain these AREs (91).  While intrinsic instability of these mRNAs 
may be mediated by RBPs such as AUF-1, a family of proteins known as the Hu-
proteins bind to the AREs and this results in stabilization (31, 47).  
 The Hu-proteins are a group of classical RBPs that share homology with the 
Dropsphila ELAV proteins. The Hu family consists of four highly homologous 
members, HuR (HuA), HuB (Hel-N1), HuC (PLE21), and HuD.  Hu proteins B, C and D 
are expressed specifically in neurons and serve as very early markers for the 
commitment stage of developing neuronal cells (63).  HuB is also expressed in the 
nervous tissue, testis, and ovaries.  HuR is the most widely expressed of the Hu 
antigens (63).  Hu proteins were first identified as target antigens of paraneoplastic 
neurological syndrome.  The presence of certain types of tumors, like small cell lung 
carcinoma, ectopic expression of antigenic neuronal Hu proteins on the cell surface 
elicits an autoimmune response, resulting in the production of antibodies.  These 
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antibodies cross the blood-brain barrier and lead to  sub-acute sensory neuropathy, 
dementia and/or encephalomyelopathy (63).  
 Structurally, the four vertebrate Hu proteins contain three ~90 amino acid–long 
RNA recognition motifs (RRMs 1-3).  The first two RRMs are positioned at the N-
terminus and are separated from the third RRM at the C-terminus by a flexible hinged 
region (63, 85).  RRMs are the most common RNA-binding domain and are 
characterized by two α-helices packed against four anti-parallel β-strands.  Structural 
studies have shown that RRM1 and 2 interact with RNA through amino acids located 
on the β-strands, in a manner similar to other RBPs (63, 85).  RRM3 has been shown to 
aid in maintaining the stability of the RNA-protein complex, implicated in protein-
protein interactions, and might also bind to poly (A) tails (31).  There is a substantial 
body of evidence that demonstrates that the Hu proteins are involved in the regulation 
of the essential steps of mRNA processing.  Some of these studies include mRNA 
export, stability, translation efficiency (46, 64), alternative splicing (105), and 
polyadenylation (106).  
 HuR, the focus of our studies, is a 36 kDa protein that is ubiquitously expressed 
and found predominantly in the nucleus.  HuR contains a shuttling sequence in the 
hinge region between RRM2 and RRM3, deemed the HNS (HuR nucleocytoplasmic 
shuttling sequence).  The HNS contains both a nuclear localization signal and a nuclear 
export signal, that allows for shuttling between the nucleus and cytoplasm (31).  HuR 
was initially suggested to function as a chaperon for mRNA ligands, accompanying 
them into the cytoplasm and providing protection from degradation (7).  Strengthening 
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this argument, HuR has been found to associate with other RBPs, such as, SETα, SETβ, 
pp32 and APRIL proteins, which have nucleocytoplasmic shuttling capabilities (63).  
Fan and Steitz revealed that overexpression of HuR resulted in an increase in  the 
stability of ARE-containing mRNAs (18)  Several others have described the ability of 
HuR to stabilize specific mRNA targets including, GLUT1 (37),  p27 (92), TNFα  (49), 
cyclin D1, p21 (47) and  cyclins A and B1 (91).  In addition, previous studies from our 
lab demonstrated that HuR binding to the GLUT1 mRNA results in an increased 
efficiency of translation initiation (24).  Additionally, Lou and Zhu established that HuR 
is able to block polyadenylation of the SV40 late (SVL) mRNA  in transfected cells (106).  
Conversely, in a recent study Meisner et al demonstrated that RRM3 of HuR contains a 
functionally conserved Me2+-binding motif in which ATP is a natural ligand (54). They 
further show that this HuR-ATP interaction is associated with terminal adenosyl 
transferase activity and RNA-modification (54). As the investigation of HuR function 
continues our understanding of the multiple mechanisms by which HuR acts to modify 
gene expression are coming to light.  
 
C/EBPβ mRNA and the RNA Binding Protein HuR. 
 Previous studies have shown that HuR is constitutively expressed in 3T3-L1 
cells and localized predominantly to the nucleus.  Within 30 minutes of induction of 
differentiation, there was a 30% increase in the cytosolic content of HuR protein (23).  
This rapid translocation of HuR into the cytosol on induction of differentiation suggests 
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that HuR plays an important function early in adipogenesis.  Gallouzi and Steitz (22) 
proposed that HuR may function as a mRNA chaperon protein during nuclear export. 
We then began to examine for potential mRNA ligands expressed very early in the 
differentiation program to determine if HuR plays a role in regulation of adipogenesis 
through binding to mRNA ligands. Cole et al. (13) established that within 2 hours of 
induction of differentiation, C/EBPβ protein could be found in the nucleus, suggesting 
that C/EBPβ mRNA must be present in the nucleus shortly after induction of 
differentiation. Examination of the C/EBPβ mRNA sequence in the 3’ UTR revealed a 
substantial ARE which we predicted could serve as a HuR binding site (Fig 4A).  
Binding of  HuR to the ARE was confirmed in vitro (23).  Further analysis of the entire 
message supports the existence of a single HuR binding site to ARE in the 3′-UTR, as 
shown in figure 4B (38).  
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Figure 4 - C/EBPβ mRNA is a Ligand for HuR in vitro. (A) 3’UTR and ARE of C/EBPβ 
mRNA (B) RNA gel shift analysis of HuR binding to C/EBPβ 3’UTR ARE (23). Lane 1 is 
radioactive probe for C/EBPβ 3’UTR only, Lane 2 is radioactive probe and 3T3-L1 
protein lysate, Lane 3 is radioactive probe, 3T3-L1 protein lysate, and HuR 3A2 
antibody, Lane 4 is the addition of non-radioactive probe (competition control) .  
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Statement of Hypothesis  
 Based on the accumulated data as well as substantial work in the field, we 
proposed that HuR binding to the C/EBPβ mRNA represents a control mechanism in 
the metabolism of this message and that HuR may play a role in the onset and 
maintenance of the adipocyte phenotype.  The work described in the body of this 
dissertation addresses this hypothesis.  
Chapter 2 – Experimental Procedures 
 
Materials 
 
 Dulbecco’s modified Eagle’s medium (DMEM) was purchased from 
Gibco/Invitrogen (Grand Island, New York). Bovine calf serum and fetal calf serum 
were purchased from Hyclone Laboratories (Logan, Utah). The 3T3-L1 cells used in this 
work were obtained from Howard Green (Harvard University, Boston, MA). 
Antibodies directed against: Cyclin A were obtained from Santa Cruz Biotechnology 
(Santa Cruz, CA). Cyclin D1 and p53 were from Cell Signaling (Danvers, MA). Cyclin E 
antibodies were from Upstate (Charlottesville, VA). β-actin antibodies were from 
Sigma (St. Louis, MO). p21 antibodies  were from Calbiochem (LaJolla, CA). The β-
tubulin antibody was a generous gift of Ted Bertrand, Department of Medicine, Brody 
School of Medicine (Greenville, NC). The antibody used as a control, anti-Armenian–
Syrian hamster monoclonal antibody was obtained from BD Pharmingen (San Diego, 
CA).  The rabbit Zfp206 antibodies Ab-1, Ab-2 and Ab-3 were the generous gift of 
Lawrence Stanton, Department of Stem Cell and Developmental Biology, Genomic 
Institute of Singapore, Singapore. The 3A2 monoclonal antibody directed against HuR 
as well as the VSV-G, C/EBPβ, and PPARγ antibodies were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA). The BCA protein assay kit, NE-PERTM cell 
fractionation kit, and HALTTM protease inhibitor mix were from Pierce. The 
siGENOME SMARTpoolTM reagent and siCONTROLTM non-targeting siRNA were 
obtained from Dharmacon (Lafayette, CO) Opti-MEM I reduced serum medium, RNase 
inhibitor, Lipofectamine 2000 were purchased from Invitrogen. The BD Retro-X 
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Universal packaging system, RevTet-OffTM system, MEF/3T3 Tet-Off cell line, vesicular 
stomatitis virus G protein (VSV-G) and enhanced green fluorescent protein expression 
vectors were obtained from BD Biosciences/Clontech. pENTR223.1-Zscan10 vector 
obtained from Open Biosystems.  pcDNA-DEST53 GatewayTM Vector, OneShot® ccdB 
SurvivalTM T1 Phage-Resistant cells, and Gatway® ClonaseTM II Enzyme Mix were 
obtained from Invitrogen. The QuikChange-XL site-directed mutagenesis kit and XL-10 
Gold Ultracompetent cells were purchased from Stratagene (Cedar Creek, TX). The 
plasmid midi kit was obtained from Qiagen (Valencia, CA). The MAXIScript T7 kit and 
KinaseMaxTM 5’end labeling kit was from Ambion (Austin, TX). SDS-PAGE 
Electrophoresis Gel reagents (ProtogelTM) were purchased from National Diagnostics 
(Atlanta, GA). All other chemicals were of reagent grade and purchased from Sigma–
Aldrich Biochemical (St. Louis, MO). Reagents for molecular biology were purchased 
from Invitrogen. 
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Methods 
 
Cell Culture 
 3T3-L1 cell culture - 3T3-L1 preadipocytes were cultured, maintained, and 
differentiated as described previously (37). Differentiation was induced 2 days post 
confluence by exposure of the cells to 115 µg/ml isobutyl methyl xanthine (MIX), 
40µg/ml dexamethasone(50), and 10µg/ml insulin in the presence of 10% fetal bovine 
serum, referred throughout the text as ―MDI‖ or ―differentiation inducers‖. Two days 
later, the culture medium was changed to medium lacking MIX and DEX, yet 
supplemented with Insulin. Two additional days later, the culture medium was 
supplemented with a decreased concentration of insulin (2.5 µg/ml); 48hrs later, insulin 
was omitted.  
 Transfections - GP2-293 packaging cells were maintained in growth medium 
consisting of DMEM with 10% fetal bovine serum (FBS) on collagen I-coated plates. 
Upon reaching 90% confluency, the medium was changed to Opti-MEM I reduced 
serum medium with 10% FBS (no antibiotics). Co-transfections of the particular β 
construct along with an expression construct for VSV-G were performed utilizing 
Lipofectamine 2000TM according to the manufacturer's recommendations. All 
transfections were accompanied by an enhanced green fluorescent protein transfection 
efficiency control. At 6 hours post-transfection, the medium was changed to fresh 
DMEM with 10% FBS. At 48 hours after the medium change, the virus particle-
containing supernatants were harvested, filtered through a 0.45-µm filter, and either 
used immediately or stored at -80 °C. A second harvest was carried out at 120 hrs.  
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Production of virus particles was confirmed by Western blot analysis for VSV-G in the 
culture supernatants. 
 
 Transductions - The multipotential MEFs (MEF/3T3 Tet-Off cell line) express the 
tetracycline-controlled transactivator and were cultured in growth medium consisting 
of DMEM containing 10% calf serum and 100 ng/ml doxycycline on 6-well plates. Cells 
were plated and transduced at 15–20% confluency by first removing one ml of spent 
media followed by the addition of 2 ml of virus particle-containing medium plus 
6µg/ml polybrene.  Cells were then spinoculated via centrifugation at room 
temperature for 90 min at 2000 rpm. Following an overnight incubation, the medium 
was changed to DMEM with 10% FBS and 100ng/ml doxycycline. For cells that would 
follow the differentiation protocol, doxycycline was removed at 50% confluency. Cells 
were allowed to reach confluency and then subject to the differentiation protocol as 
previously described with the addition of 10µM troglitizone. Notably, because of the 
high transduction efficiency (always in excess of 90%, similar to reports by Neal and 
Clipstone (59), no drug selection was required. In every experiment, control 
transductions were performed in duplicate using a construct in which expression of 
enhanced green fluorescent protein was quantified by flow cytometry. 
 SiRNA treatment of the 3T3-L1 preadipocytes - Transfection of the cells was 
performed using Dharmacon siGENOME SMARTpoolTM reagent (catalog number M-
053812-00-0020) as we have previously described (23), a four-siRNA oligo system 
designed specifically for HuR (mouse ELAV1; GenBankTM accession number 
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NM_010485 [GenBank]) by Dharmacon. Cells were transfected with siRNA using 
Lipofectamine 2000TM as a carrier according to manufacturer's instructions (Invitrogen). 
Control transfections were carried out with Lipofectamine 2000TM alone.  Briefly, 
preadipocytes were transfected in 12-well plates at 60% confluency and again 24h later 
while the cells remain pre-confluent. The cells were exposed to the transfection mixture 
for 6 h, at this time the transfection medium was replaced with Dulbecco's modified 
Eagle's medium supplemented with 10% fetal bovine serum. At 24 h after the second 
transfection, two monolayers were combined to generate immediate confluency, 48 h 
after the second transfection differentiation was initiated as we have previously 
described.  Cells were then analyzed for acquisition of the adipocyte phenotype and 
harvested at 0 time, 8, 12, 16, 20 and 24h post MDI.  
 Similar procedure was followed for Zfp206 suppression, transfection of the cells 
was performed using Dharmacon ON-TARGETplus SMARTpoolTM reagent (catalog 
number J-054446-09), a four-siRNA oligo system designed specifically for Zfp206 
(mouse Zfp206; GenBankTM accession number NM_001033425 [GenBank]) by 
Dharmacon. 
DNA Procedures 
 Preparation of C/EBPβ 3’UTR Polyadenylation Analysis constructs -
Amplification of the 324bp 3’UTR/3’end of C/EBPβ (βwt) was cloned into pCR4 TOPO 
TA vector (Invitrogen). Primers used for procedure and site directed mutagenesis are 
described in Table 1.  Briefly, the mutant C/EBPβ construct with point mutations 
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flanking the HuR binding site (βpm) was created by site directed mutagenesis using 
QuikChange-XLTM site-directed mutagenesis kit (Stratagene). This resulted in the 
creation of BglII restriction sites flanking the HuR binding site. Removal of the 101-base 
BglII fragment and subsequent replacement with a 113-base BglII fragment derived 
from the GLUT1 3'-UTR (bases 1758–1871) resulted in the creation of the mutant 
C/EBPβ construct with the HuR binding site deleted and substituted (βd/s). 
Confirmation of mutations and appropriate orientation was obtained by sequencing at 
the Genomics Core Facility East Carolina University, Greenville, NC. Constructs were 
sent to Hua Lou, Case Western Reserve, Columbus, OH for further analysis.   
 Preparation of ZFP206-GFP fusion Construct – GatewayTM Technology system 
was utilized to create a Zfp206-GFP fusion construct, a universal cloning method that 
uses site-specific recombination properties to move gene of interest into multiple vector 
systems. Briefly, the open reading frame of murine Zfp206 was inserted into 
pENTR223.1 vector by Open Biosystems. pENTR-zfp206 was used in a LR Clonase II 
reaction with pcDNA-DEST53, a GatewayTM destination N-terminus GFP fusion vector. 
Example reaction: attL1-gene-attL2 (entry clone) x attR1-ccdB-attR2(destination clone)  
= attB1-gene-attB2 (expression clone) x attP1-ccdB-attP2 (pDONR). This reaction 
resulted in a pcDNA-DEST53-ZFP206 where GFP is fused to the N-terminus of the 
ZFP206 ORF.  
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RNA Procedures 
 Immunoprecipitation of mRNP Complexes—The mRNP complexes from either 
nuclear or cytosolic fractions were immunoprecipitated and mRNA isolated using 
RNase- and DNase-free conditions by a modification of the protocol described by 
Tennenbaum et al (82). Protein A-Sepharose beads were resuspended overnight at 4 °C 
in 10 ml of HNTM buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 1 mM MgCl2, and 1% 
Triton X-100). For immunoprecipitation, 200 µg of cytosolic lysate or 100 µg of nuclear 
lysate was utilized. Seven samples were prepared for each immunoprecipitation, six for 
the isolation of RNA and one as a Western blot analysis control. Starting with the 
protein extract in HNTM buffer, the following were added to an RNase/DNase-free 
microfuge tube: Halt protease inhibitor (10 µl), vanadyl ribonucleoside complex (10 µl), 
40 units/µl RNase inhibitor (10 µl), 0.1 M dithiothreitol (1 µl), and 0.5 M EDTA (33 µl). 
The antibody was then added; for the isotype control, anti-Armenian/anti-Syrian 
hamster IgG1 monoclonal antibody was used, and for HuR, monoclonal 3A2 was used. 
Finally, the appropriate volume of lysate was added and the mixture rotated for 3 h at 
room temperature followed by the addition of protein A-Sepharose beads with 
continued mixing for an additional 2 h at room temperature. This was followed by two 
washes with HNTM buffer alone. The mixture was then centrifuged (13,200 rpm at 4 
°C) and washed three times with cold 1 M urea in HNTM buffer. One of the samples 
was taken at this time for the Western analysis control, and RNA was extracted from 
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the remaining samples using the TriZol RNA isolation protocol as per the 
manufacturer's instructions. Extracted RNA was stored at -80 °C.  
 Real Time PCR - Real-time PCR analysis was performed as described previously 
(24) with minor modifications. Briefly, total RNA (0.5 µg, integrity demonstrated by 
ethidium-stained agarose gels) was subjected to reverse transcription with random 
primers, oligo d(T) and reverse transcriptase reagents from the iScriptTM cDNA synthesis 
kit (Bio-Rad). Quantitative real-time PCR was performed with specific primers designed 
for each gene with the Beacon Designer tool (Bio-Rad). All primers were subjected to 
Blast search to ensure specificity and fold analysis to eliminate any primers with 
potential to form secondary structure. Amplification and detection were done with the 
iCycler IQ real-time PCR detection system with IQ SYBR Green Supermix (Bio-Rad). 
Standard curves were prepared for each target gene, and PCR efficiency was 
determined to be in excess of 90% for all primer sets. Threshold temperatures were 
selected automatically, and all amplifications were followed by melt-curve analysis, i.e. 
plot of the negative first derivative of the fluorescence versus temperature with the 
software assigning the melt temperature. Single-melt temperatures were recorded in all 
cases. To calculate relative C/EBPβ mRNA, the threshold cycle (CT) determined for the 
cells transduced with the empty vector (EV) (endogenous C/EBPβ) was subtracted from 
the average CT for βwt and βd/s (ΔCT), thus correcting for the minor levels of 
endogenous expression. The standard curve was generated for each real-time PCR 
determination using a dilution series (50 ng, 33.3 ng, 11.1 ng, 3.7 ng, 367 pg, 120 pg) of 
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total RNA from 3T3-L1 adipocytes (day 2). A plot of log starting quantity (ng) on the x 
axis and the CT on the y axis was utilized to determine the arbitrary C/EBPβ mRNA 
levels of the unknown samples. Real-time PCR analyses with 90% or higher efficiency 
were utilized for quantification. For multiple independent runs after normalization to β-
laminin expression, results were corrected for endogenous C/EBPβ expression using 
the CT values obtained from the cells harboring the EV. 
 Polyadenylation Length Assay - Polyadenylation of the C/EBPβ mRNA was 
determined using the primer/adapter reverse transcription-PCR method as described 
by Huarte et al. (35). The primer/adapter and primers utilized for this procedure are 
described above in Table 1. Briefly, RNA was isolated from βwt, β d/s and pRT (empty 
vector control) transduced MEF cells using TriZolTM RNA isolation protocol as per the 
manufacturer’s instructions. Reverse transcription was preformed on 3ug of RNA using 
Superscript II reverse transcriptase (Invitrogen) with oligo d(T) adapter/primer.  An 
aliquot of oligo d(T) adapter primer was then 5’end labeled with [γ32P] ATP using 
KinaseMaxTM kit (Ambion) as per manufacturer’s instructions. The labeled oligo d(T) 
adapter/primer was then purified by MicroSpin Columns (GE Healthcare) as per 
manufacturer’s instructions. Reverse transcription products (cDNA) from above were 
then used in a PCR reaction with 7.5E+05 CPM of labeled adapter/primer and 25pmol 
275nt5PA primer using illustraTM puReTaq Ready-To-Go PCR beads (GE Healthcare). 
PCR products were then extracted using phenol:chloroform:isoamyl alcohol (25:24:1) 
then precipitated for 1h with 3M sodium acetate and ethanol. Purified PCR products 
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were then separated on a 6% Acrylamide 8M Urea SequaGelTM (National Diagnostics) 
as per manufacturer’s instructions. Gels were dried under vacuum and exposed to x-ray 
film. 
 C/EBPβ mRNA Half Life Determination - The MEF-3T3 cells were transduced 
with the series of constructs and induced to differentiate as described above. At 24 h 
after induction of differentiation, doxycycline was added at a final concentration of 0.2 
µM to the cultures to stop transcription of Tet-off constructs. Total RNA was then 
isolated with respect to time, and analysis of C/EBPβ mRNA content was carried out 
using real-time PCR as described above. The data were plotted as log RNA content 
versus time. The equation y = ae-bx was fitted to the data, and half-lives were calculated. 
 RIP-CHIP (RNP Immunoprecipitation) - The mRNP complexes from total 3T3-L1 
lysate and cytosolic fractions were immunoprecipitated and mRNA isolated using 
RNase- and DNase-free conditions by a modification of the protocol described by Keene 
et al (43). Briefly, protein A-Sepharose beads were resuspended overnight at 4 °C in 10 
ml of NT2 buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1 mM MgCl2, and 0.5% IGEPAL). 
Beads were incubated with antibody at 4°C overnight; for the isotype control, anti-
Armenian/anti-Syrian hamster IgG1 monoclonal antibody was used, and for HuR, 
monoclonal 3A2 was used.  Four samples were prepared for each fraction and time 
point. A typical RIP contains the following: NT2 buffer, Halt protease inhibitor, vanadyl 
ribonucleoside complex, 40 units/µl RNase OUTTM, 0.1 M dithiothreitol (DTT), and 0.5 
M EDTA. Finally, 3mg of protein lysate was added. The protein sepharose beads 
incubated with antibody was then combined with the IP mixture and rotated for 2 h at 
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room temperature.  The beads were then washed twice with NT2 buffer alone. The 
mixture was then centrifuged (13,200 rpm at 4 °C) and washed three times with cold 1 
M urea in NT2 buffer. RNA was extracted from the IP using the TriZolTM RNA isolation 
protocol as per the manufacturer's instructions. Extracted RNA was stored at -80 °C. 
RNA was sent to Duke University Array Facility (Durham, NC) for microarray analysis.  
 
Protein Procedures 
 Isolation of Cytosolic and Nuclear Fractions - The NE-PERTM cell fractionation 
kit was used to isolate cytosolic and nuclear fractions from the 3T3-L1 cells as per the 
manufacturer's (Pierce) instructions with minor modifications. Briefly, (5) 10-cm culture 
dishes were used as a source of material for the separation. In addition to the standard 
protease inhibitors, an RNase inhibitor (Invitrogen) was added to the lysate. Incubation 
time for the initial extract was increased from 10 to 15 min. Once the cytosolic fraction 
was isolated, the nuclear fraction was subjected to a brief centrifugation, and the 
interface was removed to reduce cytoplasmic contamination. The isolated fractions 
were stored at -80C° until use. Because of high salt concentrations, nuclear fractions 
were dialyzed prior to use.  
 Western blot analysis - Protein extracts were prepared by scraping cells off 
culture dishes in 1x PBS followed by centrifugation (3000 rpm, 3min) to isolate cell 
pellets. Cell pellets were resuspended in cell lysis buffer (50mM Tis-HCl, 100mM NaCl, 
1% deoxycholic acid (Na-deoxycholate), 4% IGEPAL, 0.4% sodium dodecyl sulfate 
(SDS) and 1% HaltTM proteinase inhibitor) and frozen -80°C for at least 1h. Lysates were 
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then subjected to BCA assay and stored at -80°C until needed. Proteins were separated 
by sodium dodecyl sulfate (SDS)-PAGE, ProtogelTM (National Diagnostics) (10% gel) 
and electro-transferred to a Polyvinylidene Difluoride (PVDF) membrane (Invitrogen). 
The membranes were processed as instructed by the manufacturer, and the proteins 
were detected by enhanced chemiluminescence (LumiGloTM).  
Bioinformatics  
 Microarrays - RNA samples from 0 time and 30min cytosolic RIPs, prepared as 
previously described above, were utilized for spotted array analysis.  Oligonucleotide 
arrays were printed at the Duke Microarray Facility (Durham, NC) using Operon’s 
Mouse Genome Oligo sets, which consists of 35,852 oligonucleotide probes representing 
25,000 genes and approximately 38,000 transcripts. All arrays were subject to Loess 
normalization within each array and across all arrays using the Array Magic package in 
R (9).  Replicate probes were collapsed to one probe corresponding to the median value 
of all the replicates. Probes were filtered for a raw signal 2x greater than background. 
Log (10) ratios were then converted to log (2) ratios and IgG control IP values were 
subtracted from each matched HuR IP value. Data was gated to greater than 2 fold 
enrichment across all IPs.  The resulting data, 495 genes, were then used for further 
analysis.   
Chapter 3 
 
An Early Event in Adipogenesis, the Nuclear Selection of the CCAAT/ Enhancer-
binding Protein β (C/EBPβ) mRNA by HuR and its Translocation to the Cytosol* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Gantt, K., Cherry, J., Tenney, R., Karschner, V., and Pekala, P. H. (2005) J Biol Chem 
280(26), 24768-24774 
38 
 
Introduction 
 When confluent 3T3-L1 preadipocytes are treated with differentiation inducers, 
they synchronously reenter the cell cycle and undergo approximately two rounds of cell 
division as they enter a process that has become known as mitotic clonal expansion (29, 
65, 72). This increase in cell number and commitment to differentiation mimics the 
increase in adipose mass in obesity (19, 81).  In the 3T3-L1 preadipocytes, mitotic clonal 
expansion has been demonstrated to be required for terminal adipocyte differentiation 
(19, 61). A transcription factor expressed prior to the start of the process, C/EBPβ plays 
an essential role in the mitotic clonal expansion as well as in subsequent events in the 
differentiation program (78, 79). Transcription of the C/EBPβ gene is increased shortly 
after exposure of the cells to the differentiation inducers, and the C/EBPβ protein can 
be detected in the nucleus within 2 h (76, 101). When termination of the mitotic clonal 
expansion phase begins, C/EBPβ has been proposed to be responsible for the 
transactivation of C/EBPα and PPARγ genes, two transcription factors responsible for 
establishing and maintaining the adipocyte phenotype (70, 78). As C/EBPα expression 
is increased, C/EBPβ expression is attenuated (77). Thus, C/EBPβ plays a critical early 
regulatory role in the differentiation process.  
 HuR is an RNA-binding protein belonging to the Hu/ELAV family of mRNA-
binding proteins and is expressed in adipose (23), intestine, spleen, thymus, and testis 
with minor expression in liver and uterus (51, 52). HuR contains a nucleocytoplasmic 
shuttling sequence and functions as an adapter protein in the nuclear export of mRNAs 
that contain adenylate-uridylate-rich elements (AREs) in their 3'-untranslated regions 
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(31). Depending on the specific message, the nuclear HuR-containing messenger 
ribonucleoprotein (mRNP) is bound by APRIL and/or pp32 and then CRM1, which is 
recognized by a specific binding domain on the nuclear pore complex, facilitating 
nucleocytoplasmic transport. An alternative to the CRM1 route is mediated by 
transportin-2 binding to the HuR mRNA complex for exit through the nuclear pore (8, 
22). Once in the cytosol, HuR functions to stabilize mRNA ligands (18, 37, 49, 91, 92). 
Based on results obtained with the ectopic expression of the neuronal Hu family 
homolog HuB in both the 3T3-L1 adipocytes and human teratocarcinoma cells, HuR 
may also participate in control of translation initiation (2, 37). The selection of ligands 
and the translocation of HuR to the cytosol have been proposed to be under tight 
control (49).  
 HuR has been suggested to be involved in control of the cell cycle through 
stabilization of the mRNAs for cyclins A and B1 during S and G2, leading to increased 
expression of these proteins (91). HuR involvement in differentiation was supported by 
RNA interference knockdowns of the protein in C2C12 cells, which resulted in an 
inhibition of myogenesis coincident with decreased expression of MyoD and myogenin 
mRNAs, which are known ligands for HuR (88). Thus, it might be argued that HuR, by 
selecting specific mRNA ligands and controlling their expression, is capable of 
controlling critical events in the cell cycle as well as the differentiation process. In the 
current study we demonstrate that the C/EBPβ message is a ligand for HuR and that 
the time frame for cytosolic translocation of the complex is consistent with an early 
regulatory event in the differentiation process.  
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Results 
 HuR Expression in 3T3-L1 - In the 3T3-L1 cells HuR is constitutively expressed 
and localized predominantly to the nucleus in the preadipocytes with HuR expression 
increasing ~3-fold as the cells differentiate.  Notable is the 30% increase of HuR content 
in the cytosol with respect to differentiation. This data is consistent with HuR 
regulating the availability of relevant mRNAs for translation.  Examination of the 
C/EBPβ mRNA sequence demonstrates the presence of an ARE in the 3' UTR that 
might serve as a potential binding site for HuR. Using in vitro RNA gel shifts, we have 
demonstrated that the C/EBPβ message is a ligand for HuR (data not shown). 
 C/EBPβ mRNA and HuR Complex Formation in the Nucleus and 
Translocation into the Cytosol - To determine whether the C/EBPβ message was 
present in an mRNP complex with HuR in the intact 3T3-L1 cells, immunoprecipitations 
were performed on both nuclear and cytosolic extracts prepared at 0 and 30 min after 
the addition of the differentiation inducers, MDI.  As shown in Fig.5A. western blot 
analysis indicates that the HuR protein was detected in the nuclear fractions at both 
time points.  Additionally, a decrease nuclear presence of the HuR protein 30 min after 
induction of differentiation was readily apparent.  Analysis of the mRNA present in the 
immunoprecipitated mRNP complex shown in Fig. 5B, indicates that prior to the 
addition of the differentiation inducers, HuR-C/EBPβ complexes could not be detected.   
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Figure 5 - Formation of nuclear HuR-C/EBPβ complexes. Panel A, time course Western 
analysis confirms the presence of HuR in the immunoprecipitation. Shown is the preadipocyte at time 0 
and 30 min after exposure to the differentiation inducers. R, immunoprecipitation performed with the 
HuR monoclonal antibody; C, immunoprecipitation performed with control antibody (arrow indicates 
HuR. The other bands are the heavy and light immunoglobulin chains from the immunoprecipitations). 
Panel B, using six identical immunoprecipitations, RNA was extracted and subjected to reverse 
transcription and PCR analysis for the presence of C/EBPβ (arrow indicates C/EBPβ). Designations and 
times are as stated in panel A. M, marker of DNA ladder. +C, positive control total day 2 cDNA. –C, no 
cDNA template negative control.  
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However, within 30 min of addition of the inducers C/EBPβ mRNA was found to be 
present in the immunoprecipitated complex.  Examination of the cytosol for the 
presence of these complexes over the same time period demonstrates the presence of 
HuR protein in the cytosol (Fig. 6A) with a detectable increase 30 min after the 
induction of differentiation, consistent with translocation.  In Fig. 6B the presence of the 
C/EBPβ mRNA in the immunoprecipitated cytosolic complex at the 30 min time point 
is demonstrated.  The data presented in Fig. 5 and 6 support a model in which treatment 
of the preadipocytes with the differentiation inducers results in formation of a HuR-
C/EBPβ message complex in the nucleus, which is then followed by translocation to the 
cytosol. This incident represents a very early event in the differentiation program.   
 Effect of HuR Depletion on Adipocyte Differentiation - The proximity of the 
mRNP complex formation event, described above, to the introduction of adipogenic 
stimuli and the importance of C/EBPβ to the differentiation process has led us to 
hypothesize a role for HuR in the regulation of the onset of adipogenesis.  To support 
this hypothesis, small interfering RNA suppression of HuR protein content was 
preformed. When HuR expression was reduced the cells retained their preadipocyte 
morphology, failed to express normal levels of C/EBPβ, and did not accumulate lipid 
droplets through a 5-day time course (data not shown). 
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Figure 6 - The translocation of HuR-C/EBPβ complex to the cytosol. Panel A, time course 
Western analysis demonstrates the presence of HuR protein in the cytosol with an increase detectable at 
30 min after the induction of differentiation, consistent with translocation. R, immunoprecipitation 
performed with the HuR monoclonal antibody; C, immunoprecipitation performed with control antibody 
Panel B shows the presence of the C/EBPβ mRNA in the immunoprecipitated complex at the 30-min time 
point. Designations and times are as stated in panel A. M, marker of DNA ladder. +C, positive control 
total day 2 cDNA. –C, no cDNA template negative control.  
 
 
44 
 
Discussion 
 Our results describe the constitutive expression of the RNA-binding protein HuR 
in the 3T3-L1 preadipocytes with a modest 3-fold increase in protein content with 
respect to differentiation. At confluence, the majority of the HuR protein is retained in 
the nucleus, in a preadipocyte. However, upon exposure of the cells to the 
differentiation inducers there is a rapid formation of a nuclear HuR-C/EBPβ complex 
followed by a translocation of the complex to the cytosol. When HuR protein expression 
was reduced by siRNA, the cells exhibited an inhibition of C/EBPβ protein expression 
and an attenuation of the differentiation process.  
  These observations are consistent with maintenance of HuR protein content and 
the ability of the cells to express C/EBPβ to progress through the differentiation 
program. Our data are consistent with a step involving the HuR-mediated movement of 
the C/EBPβ message to the cytosol. Looking deeper into this process reveals that the 
proposed major pathway of cytosolic translocation from the nucleus involves 
recognition of the exon-junction complex by adapter proteins that are recognized by 
specific nucleoporins (7, 18, 22, 48). However, the C/EBPβ gene has no introns and must 
utilize an alternative export mechanism, which our data would suggest is likely 
mediated by HuR recognition of the 3'-ARE (7).  This selection of the C/EBPβ mRNA by 
HuR and mediation of its translocation to the cytosol becomes a potentially critical 
control step in the onset of adipogenesis.  In addition, these data are consistent with 
other models where cytosolic translocation of Hu proteins and their associated mRNAs 
correlated with the onset of myogenesis or neural development (82, 88).   
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 Although decreasing HuR expression using siRNA resulted in a significant 
decrease in C/EBPβ expression, we anticipate numerous ligands in which HuR binds to 
at this early event that may influence the differentiation program. We would suggest 
that the tight temporal control of specific mRNA selection and translocation to the 
cytosol during the differentiation process would be an absolute necessity and that these 
data support the existence of a new control point in the differentiation process.  In the 
next chapter we will explore the following major questions:  
 1. What is the importance of the interaction between HuR and C/EBPβ?  
 2. What is HuR regulating post transcriptionally?  
 3. What is its function?  
 4. Is it important to the adipocyte differentiation process?  
Chapter 4 
 
Post-transcriptional Control of CCAAT/Enhancer-binding Protein β (C/EBPβ) 
Expression: Formation of a Nuclear HuR-C/EBPβ mRNA Complex Determines the 
Amount of Message Reaching the Cytosol* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Karschner, V.A., Cherry, J., Jones, H., and Pekala, P. H. (2008) J Biol Chem 283(45), 
30812-30820 
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Introduction 
 Adipocyte differentiation is a complex process regulated in large part by the 
temporally controlled expression and activation of numerous transcription factors (61). 
Among these proteins, the CCAAT/enhancer-binding proteins (C/EBPs) and 
peroxisome proliferator-activated receptor (PPAR) families of transcriptional activators 
have been identified as critical to initiation of the differentiation process as well as to 
maintenance of the adipocyte phenotype (61). Functional roles for these factors have 
been established at least in part through use of the 3T3-L1 preadipocyte model system 
(61). When 3T3-L1 preadipocytes are induced to differentiate, the cells reenter the cell 
cycle and undergo mitotic clonal expansion followed by growth arrest and expression of 
the adipocyte phenotype (61), as previously described in the literature review. Briefly, 
the transcription factor C/EBPβ is expressed coincidentally with induction of 
differentiation and is essential for both mitotic clonal expansion and the transcriptional 
activation of PPARγ and C/EBPα genes (29, 81, 101, 102, 107). The indispensable nature 
of suitable C/EBPβ expression was demonstrated in studies with C/EBPβ-/- murine 
embryonic fibroblasts (MEFs), which when treated with the differentiation inducers 
could neither reenter the cell cycle and undergo mitotic clonal expansion nor express 
the adipocyte phenotype (81).  Similar results were observed in 3T3-L1 cells expressing 
a dominant-negative C/EBP (102).  
 Messenger RNA export from the nucleus, mRNA turnover, and translation 
initiation are important control points in the post-transcriptional regulation of gene 
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expression. Control of these processes, at least in part, is exerted through recognition of 
cis elements in the mRNA by specific binding proteins. One of these proteins is HuR, a 
36 kDa protein that belongs to the Hu/ELAV (embryonic lethal abnormal vision) family 
of RNA-binding proteins (69).  HuR is ubiquitously expressed, localized predominantly 
to the nucleus, and has been demonstrated to shuttle between the nucleus and 
cytoplasm. The shuttling activity suggests but has not yet proved that HuR functions by 
binding to nascent mRNAs in the nucleus and protecting them from degradation by 
actively participating in their nucleocytoplasmic transport (2, 7, 8, 18, 21, 22, 37, 42, 52, 
57). Once in the cytosol, there is compelling evidence to suggest that HuR functions to 
control the stability and translational efficiency of its ligand mRNAs (2, 7, 8, 18, 21, 22, 
37, 42, 52, 57). Recent data have also supported a role for HuR in the regulation of 
polyadenylation by competitively inhibiting the binding of the cleavage and 
polyadenylation specificity factor, thereby attenuating polyadenylation and nuclear 
export (106).  It is not clear that any one mRNA is subjected to all four HuR-mediated 
regulations, i.e. 1) control of polyadenylation, 2) translocation to the cytosol, 3) stability, 
and 4) translational initiation/efficiency.  It is important to realize that HuR is a 
regulatory protein involved in the post-transcriptional processing of certain mRNAs 
and that the particular function(s) may depend on the particular message.  
 In 3T3-L1 preadipocytes, HuR is constitutively expressed and localized 
predominantly to the nucleus (23). Within 30 min of exposure to the differentiation 
stimulus, the HuR content in the cytosol increases, consistent with HuR regulating the 
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availability of relevant mRNAs for translation. We have demonstrated in the previous 
chapter (23) that one of the relevant mRNAs forming a nuclear complex with HuR upon 
induction of the differentiation program and translocating to the cytosol as a messenger 
ribonucleoprotein (mRNP) complex with HuR is the C/EBPβ message.  
 In this study, we address the functional significance of the interactions between 
HuR and the C/EBPβ 3'-untranslated region (UTR). Using non-adipogenic MEF-3T3 
cells, we examine the effects of conditional ectopic expression of C/EBPβ and mutants 
unable to bind HuR on the metabolism of the C/EBPβ message.  
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Results 
 Ectopic Expression of Both Wild Type and Mutant C/EBPβ mRNAs in the 
Multipotential Precursor MEF-3T3 Cells - Our previous work (23) demonstrated that 
upon exposure of the cells to the differentiation inducers there is a rapid formation of a 
nuclear HuR-C/EBPβ complex followed by a translocation of the complex to the 
cytosol.  Our recent detailed analysis demonstrated the presence of a single binding site 
for HuR in the C/EBPβ mRNA.  That site is in the AU-rich element (ARE) in the 3'-UTR 
of the message (38).  Therefore, to examine the function of HuR in the translocation and 
expression of C/EBPβ mRNA, we created constructs that expressed wild type C/EBPβ 
as well as mutants that could not bind HuR, Fig 7, 1) full-length wild type C/EBPβ 
cDNA (βwt), 2) C/EBPβ cDNA with point mutations flanking the ARE (βpm), 3) 
deletion of the ARE (βdel), and 4) deletion of the ARE and substitution with a sequence 
that does not contain a HuR binding site (βd/s).  Expression of these constructs in 
murine embryonic fibroblasts resulted in significant adipose conversion relative to those 
cells expressing wild type C/EBPβ.  C/EBPβ protein content was increased markedly in 
both βdel and βd/s, which correlated with the acquisition of the adipocyte phenotype 
(Data not shown).  Analysis of the βd/s cell line demonstrated a robust expression of 
C/EBPα coincident with peroxisome proliferator-activated receptor-γ expression (Data 
not shown).  
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Figure 7 - A Schematic of C/EBPβ Mutant Constructs- Representative diagram of 
C/EBPβ mRNA indicating the approximate translation initiation sites for liver 
activating protein 1 and 2 (LAP) and liver inhibitory protein  forms of C/EBPβ, the HuR 
binding domain, and termination of transcription is shown. The graphic below 
describes the sequence alterations in the mutants.  In βwt, the uppercase bases indicate 
the sequence altered to form βpm, in which the uppercase bases indicate the mutations 
used to create BglII restriction sites in βwt.  βdel is a re-ligation of the construct after 
removal of the BglII fragment.  βd/s consists of removal of the BglII fragment and 
insertion of a 101-base fragment that does not bind HuR. 
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 Accumulation of C/EBPβ mRNA in βwt and βd/s Cell Lines- We examined the 
accumulation of total cellular C/EBPβ mRNA after removal of doxycycline and 
exposure of the cells to the differentiation mixture.  The real time PCR results shown in 
Fig 8A indicate that total RNA in both βwt and βd/s cells accumulated in a similar 
manner.  The loss of the HuR-binding ARE in βd/s had no effect on the accumulation of 
total cellular message.  This might be expected as the constructs were driven by the 
same tetracycline/doxycycline-regulated promoter.  We next examined the appearance 
and accumulation of C/EBPβ mRNA in the cytosolic compartment.  Using the Pierce 
NE-PERTM kit, we isolated cytosolic and nuclear compartments prior to and after 
removal of doxycycline and induction of differentiation, as we have described 
previously (23).  The real-time PCR data shown in Fig. 8B indicate that at all time points 
βd/s mRNA accumulated in the cytosol to a greater degree than the βwt message.  
Thus, the loss of the ability to bind HuR at the canonical ARE (present in βwt, but 
absent in βd/s) did not hinder the movement of the C/EBPβ mRNA into the cytosol.  
The previous data (Fig. 8A) indicated that total cellular C/EBPβ mRNA accumulated to 
a similar degree in both βwt and βd/s.  These data (Fig. 8B) would suggest that a 
greater percentage of the total βd/s mRNA is in the cytosol, available for translation and 
driving the accumulation of C/EBPβ protein seen earlier. To confirm this hypothesis, 
we selected the 48 hr time point and performed five independent isolations and 
subsequent determinations of the cytosolic versus nuclear distribution of βwt and βd/s. 
Those data are displayed in Fig. 8C and demonstrate that there is approximately twice 
the βd/s mRNA in the cytosol relative to the βwt mRNA.  We note that in separate 
54 
 
experiments a minimum 2-fold differential has been demonstrated to be maintained at 
least through day 8 of the differentiation program. Thus, in the absence of HuR binding, 
more C/EBPβ mRNA accumulates in the cytosol.  
 C/EBPβ mRNA Half-life—The accumulation of the βd/s mRNA in the cytosol 
could be a result of stabilization of the message upon removal of the ARE. To examine 
for this possibility, half-life determinations were made 24 h after induction of 
differentiation (Fig. 9).  The βwt and βd/s mRNAs exhibited half-lives of 120 and 60 
min, respectively, calculated using exponential decay regression. With the consideration 
that the βd/s mRNA has a more rapid half-life, the increased cytosolic accumulation is 
all the more significant.  
 C/EBPβ mRNA Polyadenylation- The data presented to this point are consistent 
with involvement of HuR in nuclear processing of the C/EBPβ message.  It would 
appear that once this mRNP complex forms, its translocation to the cytosol is 
attenuated.  To investigate the influence of HuR on nuclear processing of the C/EBPβ 
mRNA, we examined nuclear polyadenylation of the C/EBPβ transcripts from the βwt 
and βd/s cell lines.  To accumulate the data presented in Fig 9, RNA was isolated from 
the nuclear fraction and subjected to reverse transcription using an oligo (dT) 
primer/adapter followed by PCR using a forward primer located 298 nucleotides 
upstream of the site of poly(A) addition of the C/EBPβ mRNA in conjunction with the 
32P-labeled oligo(dT) primer/adapter.   
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Figure 8 - C/EBPβ mRNA from βwt and βd/s cell lines. A, total RNA was isolated with 
respect to time after removal of doxycycline from the culture medium and exposure of the cells to the 
differentiation protocol. Accumulation of total C/EBPβ mRNA was determined by real-time PCR 
analysis as described under Experimental Procedures.  The experiment was performed three times with 
identical results. B, cytosolic accumulation of C/EBPβ mRNA in βwt (Bw/t) and βd/s (Bd/s) cell lines is 
shown. The cytosolic fraction (cyto) of the cells was isolated using the Pierce NE-PER™ kit as we have 
described under Experimental Procedures. Cytosolic RNA was isolated using the TRIZol™ reagent. 
Accumulation of C/EBPβ mRNA was determined by real-time PCR analysis as described under 
Experimental Procedures. The experiment was performed three times with similar results. Data are 
plotted as the mean ± S.D.  C, the levels of βwt and βd/s mRNAs in the cytosol at the 48-h time point 
(five independent determinations) are shown. Normalization was to β-laminin mRNA, the expression of 
which does not change over the time course of the experiment, followed by correction for endogenous 
expression as discussed under Experimental Procedures. βwt content was defined as 100%, and βd/s is 
expressed relative to that value. 
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Figure 9 - C/EBPβ mRNA half-life of βwt and βd/s cell lines. At 24 h after induction of 
differentiation, doxycycline was added to the culture medium, and total RNA was isolated with respect 
to time. Real-time PCR analysis was utilized to quantify the C/EBP βwt (Bw/t) and βd/s (Bd/s) mRNAs 
remaining after addition of the doxycycline. The half-lives of the C/EBPβ mRNAs were determined 
graphically using a plot of log[mRNA] versus time as described under Experimental Procedures.  A, Real 
time results are plotted as the mean ± S.D. of two independent experiments analyzed in triplicate. B, half-
life plot of real-time results, βwt (О) and βd/s (Δ) mRNAs remaining after addition of doxycycline with 
respect to time are shown. The equation y = ae-bx was fitted to the data, and half-lives were calculated. The 
experiment was performed twice with similar results. 
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 Reverse transcription-PCR with these primers of the mRNA from the βd/s cells (Fig. 
10, lane 4) produced a smear of products ranging in size from ~300 to almost 400 
nucleotides. The minimal size predicted was 329 nucleotides (298 bp of C/EBPβ plus 31 
nucleotides of the primer/adapter). Whereas there is evidence of polyadenylation with 
βwt ( Fig. 10, lane 2), densitometric analysis indicated that it is ~35% less than that found 
in the βd/s. Notably, there is no evidence of polyadenylation occurring when mRNA 
was isolated from cells containing the empty vector (Fig. 10, lane 6).  The data suggest 
that in the absence of HuR binding, the C/EBPβ mRNA is more extensively 
polyadenylated, leading to translocation to the cytosol.  However, in βwt, which binds 
HuR, polyadenylation appears to occur to a lesser extent, with approximately one-third 
of the RNA (relative to βd/s) reaching the cytosol. Similar results were obtained using 
an RNase H-based approach for determination of poly (A) tail size for total cellular 
RNA.   
 The process of polyadenylation is a closely coupled set of reactions by which the 
3’ end of mRNA is formed. The first step of polyadenylation factors bind to the pre-
mRNA to be processed. These factors include: cleavage polyadenylation specificity 
factor (CPSF), cleavage stimulation factor (CstF), cleavage factors I & II (CFI & II) and 
polyadenylation polymerase (98).  Next, the pre-mRNA is endonucleolytically cleaved 
at a specific site about 10-30 nucleotides downstream of the poly (A) signal. Then 
during the slow step approximately 10 adenosine residues are polymerized to the 
cleaved end.  
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Figure 10 - Identification of a differential nuclear polyadenylation of C/EBPβ mRNA 
from βwt and βd/s cell lines.  Poly (A) tail lengths on βwt and βd/s were determined by reverse 
transcription-PCR poly (A) analysis of a preparation of total nuclear RNA from βwt and βd/s cell lines. 
Reverse transcription was primed with an oligo (dT) primer/adapter as described, and poly (A) tail 
lengths on the βwt and βd/s mRNAs were determined by PCR using a 5'-32P-labeled primer/adapter for 
the reverse primer and a gene-specific primer for the forward primer. The products of the PCRs were 
visualized by autoradiography after electrophoresis on 6% polyacrylamide/urea gels. Size markers are in 
nucleotides. The regions corresponding to polyadenylation of the C/EBPβ mRNA are boxed for 
comparison. Lanes 2, 4, and 6 contain the full PCRs, whereas lanes 1, 3, and 5 contain 20% of the reactions. 
The autoradiogram presented is representative of an experiment performed 3 times with similar results.  
βwt        βd/s       Control
Polyadenylated 
mRNA tails
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 Finally, the elongation step or the fast step, adds approximately 250 adenosine 
residues forming the poly (A) tail.  Recent findings indicate that U-rich sequences 
upstream of the highly conserved polyadenylation signal AAUAAA can have 
significant effects on regulation of polyadenylation (41).  The Hu proteins are known to 
bind to AU-rich regions within the same proximity as these U-rich elements (106).  
Recent in vitro assays by Zhu et al, show that mammalian Hu proteins regulate 
polyadenylation by blocking U-rich sequences (106).  These U-rich sequences were 
found to be essential for full activity of the downstream poly(A) signal sequence (41).  
In Figure 10, our data show that when HuR cannot bind to C/EBPβ mRNA, 
polyadenylation is more extensive, resulting in more message exiting the nucleus.  
These data are consistent with the hypothesis that competitive binding of HuR for U-
rich regions in the 3’UTR of C/EBPβ may cause attenuation of polyadenylation.  
Therefore, to examine the function of HuR in the regulated polyadenylation of C/EBPβ 
mRNA, we created genomic constructs that contain the 3’UTR and the downstream 
signal sequences of the wild type C/EBPβ (βwt) as well as a mutant where the ARE was 
deleted and substituted with a sequence that does not contain a HuR binding site 
(βd/s).   Expression of both constructs was under control of an SP6 promoter as detailed 
in Experimental Procedures.  These genomic constructs were then used to create 
riboprobes for a polyadenylation and cleavage assay to be preformed in collaboration 
with Hua Lou, Ph.D. Department of Molecular Genetics, Case Western Reserve 
University.  The addition of 2ug of rHuR during the incubation time course resulted in 
no significant difference in cleavage or polyadenylation between the βwt and the βd/s 
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riboprobes (Fig. 11). The band visible in figure 11 is the precursor; no visible cleaved 
product band was present. This negative result would suggest that HuR does not 
regulate the polyadenylation event of C/EBPβ mRNA in this in vitro assay system.  It is 
important to note that the polyadenylation and cleavage assay was preformed under 
controlled conditions that may have lacked in vital components specific to the 3T3-L1 
cells or this particular message required for proper regulation of polyadenylation.  With 
the consideration of the complexity of polyadenylation and plethora of components 
required for adequate measurement of HuR involvement this set of reactions, we made 
the decision to focus our efforts on the involvement of HuR in other areas of the 
differentiation program and not pursue the polyadenylation of C/EBPβ mRNA at this 
time.  
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Figure 11 - Polyadenylation and cleavage assay. Riboprobes of the 3’UTR and polyadenylation 
signal sequences were created from C/EBPβ wild type (βwt) and C/EBPβ delete substitute (βd/s) 
genomic constructs.  Each probe was incubated with 2ug of recombinant GST-HuR for 0, 30, 60, 90, or 120 
minutes at 30°C. Precursor riboprobe band visible at ~334 nt, size markers in nucleotides.   
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Discussion 
 As preadipocytes differentiate, controlled expression of C/EBPβ is essential to 
acquisition of the adipose phenotype. Transcriptional activation of the C/EBPβ gene in 
3T3-L1 cells occurs within minutes of exposure to the differentiation inducers and is 
controlled, at least in part, by the cAMP-response element-binding protein (26, 45).  In 
the differentiation program of 3T3-L1 cells, C/EBPβ first controls the entry of the cells 
into mitotic clonal expansion, and then the expression of C/EBPα and PPARγ (29, 56, 
81, 97, 101, 102, 107). The timing of expression during these processes is critical because 
C/EBPβ is promitotic and C/EBPα is antimitotic, and thus C/EBPβ expression must 
attenuate as C/EBPα expression initiates. This study describes a critical early post-
transcriptional regulation initiated in the nucleus involving formation of a HuR-
C/EBPβ mRNA complex. Formation of this mRNP appears to control the rate of 
C/EBPβ mRNA translocation to the cytosol but is not essential for the translocation 
process itself. In our previous work, we identified the HuR binding site in the C/EBPβ 
3'-UTR and demonstrated that it is the only site within the entire message (38). As 
evidenced in the data presented in Fig. 8, deletion of this HuR binding site did not 
disrupt nuclear to cytoplasmic translocation of the message. Indeed, in the absence of 
HuR binding, 2–7-fold (dependent on the time point) more C/EBPβ mRNA was 
localized to the cytosol. Conceivably, accumulation of βd/s in the cytosol could be a 
consequence of deletion of the ARE instability element, resulting in a stabilized 
message. However, as displayed in Fig. 9, the βd/s mRNA actually has a shorter half-
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life than the βwt message, making its accumulation more difficult. Overall, our data are 
consistent with C/EBPβ mRNA translocation to the cytosol occurring more readily 
when HuR is not bound, consistent with HuR functioning as an attenuator of 
movement of the complex to the cytosol.  When HuR binds to the C/EBPβ message in 
the nucleus, movement to the cytosol is not prohibited, simply diminished. The 
C/EBPβ mRNA reaches the cytosol in lower quantities and is translated into protein.  
The differentiation program is initiated and maintained. When the binding site is 
altered such that HuR cannot bind, more C/EBPβ mRNA per unit time is found in the 
cytosol. The presence of more message drives the overexpression of C/EBPβ protein, 
resulting in overexpression of C/EBPα protein and a more robust differentiation 
program.  
 In the previous chapter, siRNA reduction of HuR resulted in a significant 
decrease in C/EBPβ expression and an attenuated differentiation program.  In this 
chapter we demonstrated that the absence of a HuR binding site on C/EBPβ resulted in 
an increase amount of message in the cytosol, increased C/EBPβ protein, as well as, 
increased C/EBPα and the acquisition of the adipocyte phenotype.  Taken together 
these data are consistent with HuR functioning at an earlier time during adipogenesis, 
prior to formation of the HuR-C/EBPβ complex. As we have stated previously, we 
predict that HuR associated with numerous mRNA ligands, during the early phase of 
the differentiation program any of which may influence the process. We suggest that 
HuR may be influencing mitotic clonal expansion, which is required for proper 
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acquisition of the adipocyte phenotype.  To begin to understand the exact role of HuR in 
the differentiation process, we will address the following questions in the next chapter:  
1. Does HuR influence mitotic clonal expansion? 
2. Will suppression of HuR affect cell cycle? 
Chapter 5  
 
HuR Involvement in Mitotic Clonal Expansion during Acquisition of the Adipocyte 
Phenotype* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Vesna A. Karschner, Phillip H. Pekala. Biochemical and Biophysical Research 
Communications 383 (2009) 203-205 
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Introduction 
 Fundamental to obesity is adipocyte hyperplasia that occurs through recruitment 
and proliferation of pre-adipose cells present in the vascular stroma of adipose tissue 
(25). This hyperplasia is mimicked in culture by 3T3-L1 preadipocytes which when 
induced to differentiate, synchronously reenter the cell cycle and undergo several 
rounds of mitotic clonal expansion prior to growth arrest and expression of the 
adipocyte phenotype (61). Critical to the differentiation process is the RNA-binding 
protein, HuR (23). HuR is a 32 kDa protein containing three RNA recognition motifs 
(RRMs) and belongs to the Hu/ELAV family (embryonic lethal, abnormal vision) of 
RNA-binding proteins (31). Unlike the other three family members, HuB, HuC and 
HuD, which are exclusively neuronal, HuR is ubiquitously expressed, localized 
predominantly to the nucleus and demonstrated to shuttle between the nucleus and 
cytoplasm (17). In the nucleus, recent data have supported roles for HuR in the splicing 
as well as in the regulation of polyadenylation by competitively inhibiting the binding 
of the cleavage and polyadenylation specificity factor, thereby attenuating 
polyadenylation and nuclear export  (31, 106). In the cytosol there is compelling 
evidence to suggest that HuR functions to control the stability and translational 
efficiency of its ligand mRNAs (31).  
 Our previous work demonstrated that siRNA mediated suppression of HuR 
resulted in an inhibition of 3T3-L1 preadipocyte differentiation (23). The inhibition was 
transient, as the effect of the siRNA was lost after several days and the cells began to 
68 
 
express the adipocyte phenotype (23). Even with that consideration, those data suggest 
that during the differentiation process, there is formation of a HuR–mRNA complex 
that is essential for the differentiation program to progress. Whether the function of the 
complex is export from the nucleus or stabilization of the message, disruption of the 
interaction leads to alteration of expression and attenuation of the differentiation 
program. In terms of timing, formation of the HuR–mRNA complex has to be early in 
the process, because as we have previously demonstrated disruption of this interaction 
must precede expression of C/EBPβ (39). In addition, more than one ligand mRNA may 
be involved in the process. Our interest is in identifying these HuR ligands and 
characterizing their interaction with HuR in the context of mitotic clonal expansion and 
the differentiation program. 
 
69 
 
Results and Discussion 
 Suppression of HuR expression leads to attenuation of β-actin expression- 
Results from previous studies indicated that the β-actin mRNA was a major ligand for 
HuR on induction of differentiation (Karschner and Pekala, unpublished results). These 
data led us to examine the effect of decreased HuR expression on β-actin levels during 
the early phase of the differentiation process. Cells were transfected with siRNA 
directed against HuR as described in Experimental Procedures and induced to 
differentiate. As shown in Fig. 12, an 86% suppression of HuR expression was observed 
48 h after induction of differentiation (Lane 1) relative to mock transfected control (Lane 
2). β-actin expression decreased by 47% (Lane 1) relative to control (Lane 2). At 72 h 
(Lane 3) HuR suppression maintained at 78% of control (Lane 4) while β-actin levels 
were down by 38%. β-tubulin content was used for normalization as its levels do not 
change during the course of the experiment, moreover, it does not bind HuR. While β-
actin expression is known to decrease as the cells attain the adipocyte phenotype, this 
early decrease prior to mitotic clonal expansion might be expected to slow cell division.  
Indeed recent observations in HeLa cells by Dormoy-Raclet et al. (15) found that siRNA 
suppression of HuR led to decreased actin expression resulting in an increased 
proliferation time.  In a parallel experiment, we inhibited actin polymerization by  
 
 
 
70 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12 - Suppression of HuR expression leads to attenuation of β-actin expression. 
Cells were transfected with siRNA directed against HuR and induced to differentiate as 
described in Materials and Methods. Extracts were prepared at 48 hr and 72 hrs post-
induction of differentiation and Western blot analysis of -tubulin, β-actin, and HuR 
performed. Si, siRNA transfected cell lysates. M, mock transfected cell lysates. 
Quantification of protein levels was performed using scanning densitometry. 
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exposure of the cells to cytochalasin D and examined the effect on differentiation and 
used C/EBPα as marker for terminal differentiation. The cytochalasin D treated cells 
maintained an altered morphology and never accumulated lipid, in addition, on day 8 
post-induction of differentiation, C/EBPα protein levels were only 30% of that found in 
the untreated cells (Karschner and Pekala, unpublished results). These data were 
similar to what we observed for C/EBPα expression in cells treated with siRNA 
directed against HuR, providing further confirmation of the importance of actin 
expression (polymerization) for appropriate induction of differentiation. In their study, 
Dormoy-Raclet et al. (15) observed that key β-actin mediated functions including cell 
adhesion, migration and invasion, were markedly decreased and these defects 
correlated with the loss of the actin stress fiber network.  In addition there is significant 
evidence to link down-regulation of β-actin expression to signaling processes that 
control transcription (33, 71).  
 Effect of decreased HuR expression on the expression of Cyclins A, E, and D1 - 
To examine the influence of HuR on mitotic clonal expansion, we used siRNA to 
suppress HuR expression, induced differentiation and examined three cell cycle 
components. As shown in Fig. 13A, suppression of HuR was in excess of 85% at 0, 8, 
and 12 h after induction of differentiation and 70% for the 16, 20, and 24 h time points. 
With this degree of HuR depletion, Cyclins A, E, and D1 were expressed at apparent 
lower levels and on a slightly delayed (4–8 h) time course (Fig. 13C) than that observed 
for the mock transfected cells (Fig. 13B). 
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Figure 13 - Effect of decreased HuR expression on the expression of Cyclins A, E, and 
D1.  siRNA mediated suppression of HuR expression was performed as detailed in 
Materials and Methods. Cells were induced to differentiate and extracts prepared over a 
24 h period. Western blot analysis was performed to determine HuR content (A) as well 
as that of Cyclins A, E, and D1 in mock (B) and siRNA (C) treated cells. Si-siRNA 
transfected cell lysates. M- Mock transfected cell lysates. Quantification was by 
scanning densitometry.  
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The data are similar to those reported by Dormoy-Raclet et al. (15), a study in which 
depletion of HuR lead to an attenuation rather than an inhibition of movement through 
the cell cycle. However, one must consider that Dormoy-Raclet et al. (15) were working 
with cells that had lost contact inhibition of growth and were constantly moving 
through the cell cycle, while in our study, the 3T3-L1 cells had attained contact 
inhibition of growth and on induction of differentiation synchronously reenter the cell 
cycle, also known as, the mitotic clonal expansion phase of the differentiation program.  
 siRNA mediated suppression of HuR leads to a transient suppression of p53 
and p21 - Using the same extracts we examined for alterations in the expression of p53, 
reported to be activated as a consequence of down-regulation of actin expression 
and/or loss of cytosolic actin filaments (71). As shown in Fig. 14, we observed a 
transient, near 60% decrease in p53 expression at the time of induction of 
differentiation. The p53 mRNA has a HuR binding site in the 5’-UTR and the interaction 
is thought to control translational efficiency, thus, loss of HuR led to decreased p53. We 
also examined for expression of the adipocyte phenotype. We should note that both p53 
and p21 are expressed at significant levels throughout the differentiation program (36). 
While the level of expression does not address activation there is ample evidence 
consistent with a requirement for both proteins for a productive differentiation 
program. Interestingly, in the next chapter we examined for potential mRNA ligands of 
HuR using an RNA Immunoprecipitation–CHIP assay (43).  
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Figure 14 - siRNA mediated suppression of HuR leads to a transient suppression of 
p53.  Cells were prepared for experimentation as detailed in the legend to Fig. 2. 
Extracts were prepared from siRNA and mock transfected cells and Western blot 
analysis performed for p53 (A). Si-siRNA transfected cell lysates. M- Mock transfected 
cell lysates. Quantification was by scanning densitometry (B).  
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 In this analysis both β-actin and p53 were demonstrated to be ligands of HuR, while 
p21 was not (see Appendix p119). This would suggest that when HuR protein content 
was decreased, the resulting mRNAs coding for β-actin and p53 were also decreased 
leading to decreased β-actin and p53 protein.  It appears likely that the decrease in p21 
protein may be mediated by loss of p53 and thus decreased transactivation of the p21 
gene. Taken together down-regulation of β-actin, p53 and p21 expression most certainly 
leads to a decreased ability of the cells to undergo mitotic clonal expansion efficiently. 
Thus, our data are consistent with HuR controlling the expression of a number of gene 
products that individually could influence/attenuate the progress of the differentiation 
program. To discover additional mRNA ligands of HuR that are critical to the 
differentiation process, we will address the following in the next chapter:  
1. Microarrays, can we dissect out HuR mRNA ligands (gene sets) that are 
different between 0 time and 30 min post induction of differentiation? 
2. Identify new gene products that are crucial to adipogenesis. 
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Figure 15 - siRNA mediated suppression of HuR leads to a transient suppression of 
p21.  Cells were prepared for experimentation as detailed in the legend to Fig. 13. 
Extracts were prepared from siRNA and mock transfected cells and Western blot 
analysis performed for p21 (A). Si-siRNA transfected cell lysates. M- Mock transfected 
cell lysates. Quantification was by scanning densitometry (B). 
 
 
Chapter 6 
 
RIP-CHIP Analysis of HuR Ligands in 3T3-L1 preadipocyte cells reveals the 
expression of Zfp206, a transcription factor involved in ES cells pluripotency.* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Vesna A. Karschner and Phillip H. Pekala 
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Introduction 
   Fundamental to obesity is adipocyte hyperplasia that occurs through 
recruitment and proliferation of preadipose cells present in the vascular stroma of 
adipose tissue (25, 74).  This hyperplasia is mimicked ex vivo by post-confluent 3T3-L1 
preadipocytes which when induced to differentiate, synchronously reenter the cell cycle 
and undergo several rounds of mitotic clonal expansion prior to growth arrest and 
expression of the adipocyte phenotype (81, 101).  
 The 3T3-L1 adipocyte differentiation program is controlled by a cascade of 
transcription factors (fig 2 & 3), that includes the CCAAT/enhancer binding proteins 
(C/EBPs) and a nuclear hormone receptor, peroxisome proliferator activated receptor γ 
(PPARγ) (19). Superimposed on this signal cascade of C/EBPs and PPARγ expression is 
the embryonic stem cell transcription factor, Zfp206, which we have recently identified 
through a RIP-CHIP microarray analysis.   
 Zfp206 (NM_00103345), belongs to the family of SCAN domain-containing poly 
C2H2 zinc finger proteins, which is associated with a large family of transcription factors 
found exclusively in vertebrates (93, 104).  Zfp206 is located in a gene cluster on 
chromosome 17 and encodes a 782 amino acid protein (88.4 kDa) that contains 14 zinc 
fingers and a SCAN-domain.  Generally, transcription factors that contain many C2H2 
zinc fingers, one of the most versatile DNA-recognition motifs, are thought to have 
multiple ligand specificities and in some cases bind to single or double stranded RNA 
(93, 104).   The SCAN domain is a highly conserved motif (84 residues) that functions as 
a protein interaction domain and mediates self-association or selective association with 
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other proteins by mediating homo- and hetero-oligomerization (93, 104).  Proteins 
containing SCAN domains with multiple zinc-fingers represent a subgroup of 
eukaryotic transcription factors that have been implicated in cell survival and 
differentiation. 
 Functional gene expression surveys of the mouse genome suggest that Zfp206 is 
expressed almost exclusively in embryonic stem cells (ESC) (103).  Detailed analysis 
indicated that upon differentiation of human and mouse ESC, Zfp206 (ZNF206 in 
human) is highly expressed in pluripotent ESC and throughout certain areas of the 
developing embryo, but was absent in differentiated or adult tissues (93).  Zhang et al. 
confirmed this observation by demonstrating that Zfp206 expression decreased rapidly 
upon differentiation of cultured mouse ESC and during development of mouse 
embryos (104).  Furthermore, they demonstrated that Zfp206 strongly regulates the 
levels of a handful of transcription factors whose expression is also specific to ESC and 
early stages of development. These genes encode apparent regulators, such as, eIF-1A, 
Tcstv1 and Zscan4 (104).   
   The current data has demonstrated that the previously uncharacterized Zfp206 
gene functions as a positive regulator of pluripotency in ESC and is down-regulated 
upon differentiated states (6, 104).  The following study describes the expression of the 
transcription factor Zfp206 in preadipocytes and the role it plays in the regulation of 
adipogenesis. 
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Results 
 RIP-CHIP Analysis Reveals New HuR Ligands during Adipogenesis - In the 
previous chapters we described the involvement of the RNA binding protein HuR in 
the regulation of adipocyte differentiation.  Our work demonstrated siRNA suppression 
of HuR expression led to an inhibition of the 3T3-L1 differentiation program; an 
observation consistent with a critical role for HuR in adipogenesis (23).  Previous to this, 
our studies have focused on one HuR ligand, the C/EBPβ mRNA.  In order to identify 
other HuR ligand mRNAs early in the differentiation program, we used antibodies 
directed against HuR to perform an RNP immunoprecipitation−microarray (RIP-Chip) 
analysis, as described in Experimental Procedures.  This permitted the identification of 
a discrete subset of mRNAs associated with HuR, as the population of mRNPs changed 
markedly during the initial 30 minutes of the adipocyte differentiation program.  The 
RIP-Chip analysis identified 495 individual mRNAs that served as ligands for HuR in 
this time frame, see appendix A.  Figure 16A, shows the distribution of HuR ligand 
mRNAs at 0 time and 30 minutes post differentiation. The data describe a unique subset 
of 193 mRNA ligands found only at 0 time, and 30 min post induction of differentiation 
45 mRNA ligands unique to this time point were identified.  We focused our efforts on 
the subpopulation of 45 mRNAs that were not ligands at 0 time but become markedly 
enriched 30 minutes after induction of differentiation.  One such ligand identified was 
Zfp206 (Fig. 16B).   
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Figure 16 - Charts of HuR RIP-CHIP Gene Enrichment Data. A. Venn diagram 
showing distribution of genes (mRNA ligands) at 0 time and 30min post MDI 
treatment. 450 mRNA ligands identified for 0 time, 302 mRNA ligands identified at 
30min, 257 mRNA ligands are common between 0 and 30 min, 193 mRNA ligands are 
unique to 0 time, and 45 mRNA ligands are unique to 30 min.  B. Scatter plot of gene 
enrichment scores of HuR mRNA ligands at 0 time vs. 30 min post MDI treatment. The 
position of Zfp206 is shown on plot, enrichment score (-0.082, 3.49).  
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 Characterization of Zfp206 in 3T3-L1 Preadipocyte and Adipocyte - Detection of 
Zfp206 mRNA from the RIP-Chip assay was confirmed by RT-PCR using RNA isolated 
from the 3T3-L1 cells during a differentiation time course. As shown in Fig. 17A, Zfp206 
mRNA was detectable at day 0 and expressed at a consistent level through day 7 of the 
differentiation program, after which decreased to undetectable levels by day 9. 
Expression of PPARγ mRNA during the same differentiation time course is displayed in 
Figure 17B for comparison. 
  Western blot analysis of Zfp206 protein levels during the differentiation time 
course detected two protein species.  As shown in Fig. 18, an 88 kDa protein 
corresponding to the full length gene product was detected at day 0 which was 
maintained through day 3. At which (day 3), a transient ~ 32 kDa isoform was detected 
at low levels reaching maximal expression by day 7, and then decreasing to 
undetectable levels by day 11. 
 Examination of the gene annotation using the Ensembl Gene Browser 
(http://www.ensembl.org) indicated that Zfp206 is also known as Zscan10 and 
genomic evidence suggests the existence of up to 8 potential splice variants (Fig. 19). 
One of these, Zscan10.201, is approximately 33.5 kDa making it a potential candidate for 
the ~ 32 kDa protein species identified in figure 18.  Recent work in embryonic stem 
cells has identified at least nine isoforms of Zfp206, including seven splice variants (93, 
104).  
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However, the description of the variant Zscan10.201 has not been identified.   As shown 
in Figure 19, the alternative splicing event leading to the formation of Zscan10.201 
results in the preservation SCAN domain and the loss of the zinc finger domain of the 
protein.  
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Figure 17 - Zfp206 and PPARγ mRNA expression in 3T3-L1 A, RT-PCR analysis of 
Zfp206 mRNA expression over a 3T3-L1 differentiation time course. – Ctr lane is 
primers only. + Ctr lane is ESC RNA.  B, RT-PCR analysis of PPARγ mRNA expression 
over the same 3T3-L1 differentiation time course in A.  
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Figure 18 - Zfp206 protein expression in 3T3-L1 cell line. Western Blot analysis of 
Zfp206 protein expression over a 3T3-L1 differentiation time course. Zfp206 full length 
(88 kDa) and Zscan10.201 isoform (33 kDa) shown by arrows. 
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Figure 19. Gene Annotation of Zscan10. Adaptation of Ensembl genomic annotation 
for Zscan10 Mus musculus. Black to gray scale boxes represents exons 1-6. Protein 
coding, SCAN and Zinc finger domains illustrated in blue. Red arrows depict primers 
used in RT-PCR analysis.  
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 Zfp206-GFP fusion protein localizes to the nucleus of 3T3-L1 -  Zfp206 has been 
characterized as a transcription factor that is highly expressed in embryonic stem cells 
and is promptly repressed upon differentiation into to various tissue lineages (93). 
Based on our recent data, Zfp206 follows a similar expression pattern (Fig. 18). We 
hypothesized that overexpression of Zfp206 in the 3T3-L1 cell line would prevent or 
lessen the degree of differentiation into adipocytes. To begin to test this, we have 
created a Zfp206-GFP fusion construct, by inserting the open reading frame of Zfp206 
into an N-terminal GFP fusion vector. The Zfp206-GFP plasmid was then transfected 
into 3T3-L1 cells and monitored by microscopy for GFP at 48hrs post transfection.  As 
shown in Fig. 20J&G, cells transfected with the Zfp206-GFP construct demonstrated 
GFP expression localized to the nucleus. Conversely, the control IRES-EGFP vector (Fig. 
20A-E) demonstrates GFP expression throughout the entire cell. This data suggests that 
Zfp206 is localized to the nucleus of the 3T3-L1 cell and supports Zfp206 functioning as a 
transcription factor. Further examination of how Zfp206 overexpression affects 
differentiation is currently being tested.   
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Figure 20. Zfp206-GFP fusion protein localizes to Nucleus. Phase and fluorescent 
images of 3T3-L1 cells, 48hrs post transfection with either IRES-EGFP or ZFP-GFP 
plasmids.  A. Phase contrast, IRES-EGFP. B. Fluorescent clear filter, cell expressing 
IRES-EGFP (same cell as A). C. Fluorescent GFP, cell expressing IRES-EGFP. D. 
Fluorescent GFP, cell expressing IRES-GFP. E. Fluorescent GFP, cell expressing IRES-
EGFP. F. Phase contrast, ZFP-GFP. G. Fluorescent GFP filter, ZFP-GFP (same cell as F). 
H. Merge of F and G images. I. Phase contrast, ZFP-GFP. J Fluorescent GFP, ZFP-GFP 
(same cell as I). K. Merge of I and J images.    
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 Zfp206 gene expression in 3T3-L1 is not regulated by Oct4/Sox2 -  In embryonic 
stem cells, Zfp206 gene expression is regulated by Oct4 and Sox2, which are embryonic 
transcription factors known to play important roles in the maintenance of embryonic 
stem cell pluripotency (94). The presence of two composite sox-oct binding elements 
within the first intron of Zfp206 has been shown to activate transcription synergistically 
(94).  To determine if Oct4 and Sox2 maybe relevant to the control of Zfp206 expression 
in the 3T3-L1 cells we examined for their expression, RNA was isolated from a 
differentiation time course and examined for the presence of both Sox2 and Oct4 mRNA 
via RT-PCR. As shown in figure 21, neither Sox2 mRNA nor Oct4 mRNA were present 
in 3T3-L1 cells relative to that found in the D3 murine ESC line. These data suggest that 
Zfp206 gene regulation is cell type specific and Oct4/Sox2 is not required for 
transcriptional activation of Zfp206 in the 3T3-L1 preadipocyte cell line.    
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Figure 21 - Oct4 and Sox2 mRNA Expression in the 3T3-L1 Differentiation Time 
Course. 3T3-L1 RNA was harvested at 0 time, day7, and day 11 post MDI treatment and 
analyzed by RT-PCR with primers for Sox2 and Oct4.  Lane 1, DNA 100bp ladder. Lane 
2-4, 3T3-L1 0 time, day 7, and day 11, respectively. Lane 5, positive control embryonic 
stem cell line D3. Lane 6, negative control H2O. 
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 Zfp206 is not down-regulated in C/EBPβ null MEF cell line - To further 
investigate the regulation of Zfp206 we utilized C/EBPβ null mouse embryonic 
fibroblasts (C/EBPβ-/-). These cells were harvested from 13.5 day embryos that had been 
derived by mating C/EBPβ +/- mice.  The C/EBPβ-/- MEFs will not differentiate when 
stimulated with induction cocktail. Cells were grown to confluency and induced to 
differentiation as described in Experimental Procedures. Cells were maintained for 11 
days post induction of differentiation and the preadipocyte morphology was conserved. 
As shown in Fig. 22, western blot analysis of C/EBPβ-/- MEFs at days 0, 7 and 11 post 
induction of differentiation demonstrated that Zfp206 expression was maintained 
throughout the differentiation time course. This expression pattern differs from that of 
the 3T3-L1 cells where Zfp206 is down regulated after day 7 of induction of 
differentiation (Fig.18). Interestingly, expression of Zscan10.201 splice variant was not 
observed.  
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Figure 22 . Zfp206 expression in C/EBPβ-/- MEF cell line. C/EBPβ-/- MEF cells were 
induced to differentiate and harvested at day 0, 7, and 11. Protein samples were 
analyzed by western blot for Zfp206 (88 kDa). Absence of Zscan10.201 observed (32 
kDa).  
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 Zfp206 Expressed in Human Preadipocytes but not in Adipocytes - Cultures of 
human subcutaneous preadipocytes and adipocytes (2 wks post differentiation) were 
obtained from Zen-Bio, Inc. and maintained as described in Experimental Procedures. 
Analysis of Zfp206 protein expression in the human cell was carried out by use of the 
murine Zfp206 antibody which shares 60% homology with the human protein. As 
shown in Fig. 23A, the 88 kDa full length species was detected in the preadipocyte and 
similar to that observed in the 3T3-L1 cells (Fig.18), down regulation was observed in 
the mature human adipocytes. Further confirmation was obtained by examination of 
Zfp206 mRNA levels by RT-PCR. As shown in Figure 23B, Zfp206 mRNA was detected 
in the human preadipocyte and was absent in the adipocyte. Importantly, these data 
demonstrate that Zfp206 expression is not an artifact of the 3T3-L1 cells or the culture 
system; and its expression and down regulation in primary human cells is consistent 
with the involvement of this embryonic stem cell transcription factor in the 
differentiation program of human preadipocytes.  
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Figure 23 - Zfp206 Expression in Human Subcutaneous Preadipocyte and Adipocytes. 
A- Western blot analysis of preadipocyte (PA) and adipocyte (Ads) lysates. B- 
Coomassie Brilliant Blue R Staining of the blot shown in Panel A to demonstrate protein 
loading. C- RT-PCR of RNA isolated from 2 week post differentiated adipocytes.  
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 Analysis of Suppression of Zfp206 mRNA by Quantitative PCR - Our 
hypothesis, based on the current but limited literature on Zfp206, is that expression of 
Zfp206 is part of a mechanism for maintenance of the preadipocyte differentiation 
potential, and as the adipocyte phenotype is established, expression of Zfp206 is 
diminished. It may be that as PPARγ expression achieves homeostatic levels, locking in 
the adipocyte phenotype, and Zfp206 expression is down regulated.  To begin to 
address our hypothesis, we have attempted to suppress Zfp206 via several methods as 
described below, with minimal to no effect of Zfp206 expression.  
 Attempts at suppression of Zfp206 by use of siRNA-Zfp206 transiently 
transfected into 3T3-L1 cells resulted in no significant suppression of protein when 
examined by western blot analysis (data not shown). Six independent troubleshooting 
trials were preformed, the following are the conditions tested: Single dose transfections 
of siRNA Zfp206 at 60% and 90% confluency, Double dose (consecutive transfections 
24hrs apart) of siRNA Zfp206 at 60% and 90% confluence, varying harvest times at 48hr, 
72hr and 96 hrs post transfection, and with or without combination of transfected 
monolayers for immediate confluence. The reason for these failures is unknown. We 
have used this same siRNA system (Dharmacon SMARTpool) for suppression of HuR 
in previous studies with higher then 80% suppression of the protein.  
 Next we utilized two Zfp206 shRNA constructs (gifts from Larry Stanton) for 
transiently transfections into 3T3-L1 cells. Two independent troubleshooting trials were 
preformed testing the following conditions: 1. Cells were harvested at 48hrs and 72hrs 
post transfection, with combined monolayers for immediate confluence 2. Cells were 
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harvested at 92hr, 144hr, and 192hrs, without combining monolayers. Treatments 
included sh1 & sh2 independently and collectively.  These trials resulted in no 
significant suppression of the protein when examined by western blot (data not shown). 
The failures of these attempts are assumed to be caused by low transfection efficiencies. 
 Cell lines were created by stable transfections of shRNA constructs into the 3T3-
L1 cell line to select for a pure shRNA expressing population. However, no effect was 
observed. Both 3T3-L1-sh1Zfp and 3T3-L1-sh2Zfp expressed Zfp206 protein equal to 
that of the control 3T3-L1 cells (data not shown).  
 Larry Stanton was able to show that Zfp206 mRNA levels decrease during 
differentiation of ES cells by quantitative PCR (qPCR) (104) Using the same qPCR 
primers for Zfp206 we attempted to show suppression of Zfp206 mRNA by siRNA and 
shRNA independently. Zfp206 mRNA content was first determined by qPCR on days 1, 
7 and 11 of a differentiation time course.  Zfp206 mRNA content was observed to be 
maximal on day 1 after induction of differentiation; by day 7 mRNA levels were 
significantly diminished and remained reduced through day 11 (Fig. 24A). These data 
are consistent with the Zfp206 protein expression profile, (Fig. 18).  
 In our next qPCR trial we attempted to suppress Zfp206 expression by siRNA 
and shRNA, and then analyze Zfp206 mRNA content at 24 hour and 48 hours post 
transfection, as displayed in Fig. 24B&C.  Approximately 60% and 80% suppression of 
Zfp206 mRNA was observed at 24hrs and 48hrs, respectively.  The results demonstrate 
a possible trend towards mRNA suppression.  However, data from these trials had 
extremely variable threshold values and therefore are not reliable. To better understand 
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the variability seen in the qPCR results we sought help from the qPCR specialist at 
BioRad, Inc. It was their opinion that the primer melt curves for β-laminin (control) 
primer and Zfp206 were valid. They suggested that we should alter the annealing 
temperature from 64°C to 60°C; this had no overall effect on results. 
 Analysis of standard curve data for the two sets of primers utilized a dilution 
series ranging from 500ng of 5pg of Day 1 3T3-L1 cDNA. The standard curve generated 
from the β-laminin primers is depicted in figure 25A, which shows a valid standard 
curve and equation.   
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Figure 24. Quantitative PCR analysis of Zfp206 mRNA suppression. A. At day 1, 7 
and 11 post induction of differentiation, total RNA was isolated from 3T3-L1 cells and 
subjected to RT-qPCR with Zfp206 specific primers. B. Total RNA isolated from siRNA, 
shRNA or Lipofectamine 2000 control treated 3T3-L1 cells 24hrs post transfection was 
subjected to RT-qPCR with Zfp206 specific primers. C. Forty-eight hour time point, 
same conditions as panel B. B&C are representative of the best data from 5 independent 
qPCR trials. Percentages in parentheses are percent reduction in expression.  
 
 
101 
 
A
B
C
102 
 
 However, the standard curve data for the Zfp206 primers with the same serial dilution 
of cDNA shows an erratic display of threshold cycle values (Ct) independent on 
concentration of starting material (Fig 25B). The data produced do not constitute an 
acceptable standard curve and the equation of y=-0.229x + 29.35 is almost a straight 
horizontal line. It was concluded that the Zfp206 primers used fail to amplify a true 
amplicon in 3T3-L1 cells and therefore all data produced with Zfp206 primers are null 
and void.  It is possible that the targeted region of mRNA of these primers is highly 
structured and difficult to access.  Further analysis of these primers using RNA fold 
prediction software showed a hairpin structure formed between the forward and 
reverse primers. Future attempts at qPCR for Zfp206 mRNA will require new primer 
design.  
 Further analysis is needed to determine whether suppression of Zfp206 can be 
established and whether its suppression will affect the 3T3-L1 differentiation protocol. 
Studies using Lentiviral shRNA constructs are underway.  
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Figure 25. Real Time PCR Standard Curve Data. A. Standard curve of 3T3-L1 day 1 
cDNA with β-Laminin primers, standard curve equation for arbitrary RNA mass 
shown, acceptable standard curve. B. Standard curve of 3T3-L1 day 1 cDNA with 
Zfp206 primers, standard curve equation for arbitrary RNA mass shown, not acceptable 
standard curve, target not amplified.  
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Discussion 
 The Zfp206 mRNA was identified among 495 HuR ligands in a RIP-ChIP 
microarray analysis.  Prior to this, Zfp206 had been described as being exclusively 
expressed in embryonic stem cells by Wang et al. (93) and Zhang et al. (103, 104). Our 
array data indicated that at 0 time, the Zfp206 mRNA was not a ligand for HuR, yet at 
30 min after induction of differentiation the complex was detected. Zfp206 mRNA was 
detected via RT-PCR in the 3T3-L1 preadipocyte at 0 time. The data suggest that the 
HuR binding site may initially (0 time) be occupied by another protein complex. Indeed, 
differential occupation of an adenylate-uridylate rich site in other mRNAs has been 
demonstrated for HuR and AUF-1 (47). 
  Our findings demonstrate that Zfp206 protein is expressed in confluent 3T3-L1 
preadipocytes and expression is maintained through the first three days post induction 
of differentiation. As the cells become fully differentiated, Zfp206 expression is 
terminated. Additionally, an approximate 32 kDa splice variant (Zscan10.201) was 
observed on day 3 post induction of differentiation with its expression diminished as 
the cells reach terminal differentiation.  The splice variant Zscan10.201 maintains an 
intact SCAN domain but has lost the zinc finger domain of the protein, thus it can no 
longer bind DNA. This combination of domains or lack of domains, leads to the 
hypothesis that this variant may serve as a dominant-negative form of Zfp206. The 
SCAN domain is preserved and can potentially interact with other protein partners 
involved in either gene activation or repression.  Recent work has demonstrated that 
Zfp206 can bind to more than 3,500 sites in the genome of embryonic stem cells (100). 
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Target genes include those involved in nucleic acid metabolism and several genes that  
encode pluripotency-regulating transcription factors, such as Klf2, Klf4, Zfp281, Oct4 and 
Sox2 (100).  Examination of 10 of these genes indicated that Zfp206 binding could 
activate, suppress or have no effect on the rate of transcription.  Interestingly, Oct4 and 
Sox2 expression is regulated by Zfp206 through direct recruitment to their promoter 
regions.  Correspondingly, Oct4 and Sox2 reciprocally regulate the expression of Zfp206 
by directly binding to the Zfp206 promoter (100).  
  Zscan10.201 could potentially act as a Zfp206 binding partner sink, sequestering 
potential partners inhibiting their binding to the full length Zfp206 and thus preventing 
gene activation and/or repression. Our hypothesis would suggest that this inhibition of 
Zfp206 function would permit the 3T3-L1 cells to enter a terminally differentiated state.  
This hypothesis has yet to be proven, but will be the focus of future studies.  
 In embryonic stem cells, Zfp206 gene expression is regulated by the transcription 
factors Oct4 and Sox2 (94). Conversely, our findings show that Oct4 and Sox2 are not 
expressed during the differentiation of 3T3-L1 cells, suggesting that another mode of 
regulation must be in effect.  Future studies will define the promoter region of the 
Zfp206 gene and elucidate the regulatory elements that control expression of Zfp206 
during differentiation.   
 The Zfp206 protein expression profile in the C/EBPβ-/- MEFs differs from that of 
the 3T3-L1 cells, in that, Zfp206 is not down-regulated as seen in the mature adipocyte. 
Our C/EBPβ-/- MEF data is consistent with the hypothesis that Zfp206 plays a role in 
the differentiation program. The absence of C/EBPβ protein in these cells effectively 
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prevents activation of the differentiation program and thus the adipocyte phenotype is 
never established and Zfp206 is not down-regulated. Interestingly, there are several 
C/EBPβ and C/EBPα binding sites within the purported enhancer/repressor regions of 
the Zfp206 gene (unpublished data).  This would be consistent with either direct or 
indirect C/EBPβ involvement in control of expression of both Zfp206 and Zscan10.201.    
 Our data indicate that human preadipocytes, isolated from subcutaneous fat 
depots of female donors, express Zfp206. We also demonstrate that human 
preadipocytes that were induced to differentiate to adipocytes show a down-regulation 
of Zfp206 protein. These findings show a similar pattern of expression as the 3T3-L1 
preadipocyte cell line. Further studies of Zfp206 expression and role in human 
preadipocyte tissue may lead to clinically significant findings that may be applied to 
obesity.  
 Attempts at suppressing Zfp206 mRNA by siRNA/shRNA illustrate the 
potential to decrease Zfp206 mRNA by eighty percent 48 hours after transfection.  
Further manipulation of this method is needed such that protein levels are affected and 
the role of Zfp206 in the differentiation program is clarified.  Based on our hypothesis 
we predict that loss of Zfp206 will result in a spontaneous initiation of the 
differentiation program with a rapid onset of the adipocyte phenotype i.e. early 
expression of the C/EBPs and PPARγ as well as early deposition of lipid.  
 Figure 26 summarizes the protein expression pattern of Zfp206 in context with 
PPARγ and the C/EBP family of transcription factors during the differentiation process.  
As PPARγ and C/EBPα protein levels rise and the cells enter into terminal 
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differentiation, Zfp206 protein diminishes.    Further studies will be required to fully 
elucidate the mechanism(s) by which Zfp206 regulates transcription levels of its 
putative targets and by which it influences adipocyte differentiation. If we are to 
identify new diagnostic biomarkers and discover new treatment options for obesity, we 
need to understand the regulation of the differentiation process as well as the 
maintenance of the differentiated phenotype in this complex tissue.  
Chapter 7- DISCUSSION  
 Gene expression in eukaryotes is extensively controlled at the post-
transcriptional level by RNA-binding proteins and ribonucleoprotein complexes 
modulating the maturation, stability, transport, editing and translation of RNA 
transcripts.  Our studies describe an RNA binding protein, HuR, which interacts with 
AU-rich elements in the 3’ untranslated region of mRNAs.  Many of the genes which 
possess AU-rich elements regulate transient biological responses, including cell growth 
and differentiation, immune responses, signal transduction, hematopoiesis, apoptosis, 
and metabolism.  Our studies focus on the involvement of HuR in the 3T3-L1 
preadipocyte cell and during induction of differentiation into a mature adipocyte. 
 With the realization that HuR shuttles between the nuclear and cytosolic 
compartments, our work has demonstrated that upon confluence the bulk of HuR 
protein is retained in the 3T3-L1 cell nucleus.  However, on exposure to the 
differentiation inducers the distribution is altered with the cytosolic content doubling in 
the first 30 min.  We have further demonstrated that suppression of HuR protein 
expression resulted in an attenuation of the differentiation program with one of the 
downstream effects being an inhibition of C/EBPβ protein expression.  
 As we have stated previously, we predict that HuR associates with numerous 
mRNA ligands during the early phase of the differentiation program, any of which may 
influence the process.  Adipogenesis requires a sequence of events including growth 
arrest of proliferating preadipocytes, synchronous reentry into the cell cycle from G0 
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followed by limited mitotic clonal expansion, and growth arrest prior to terminal 
differentiation during which lipid accumulation occurs.  Thus, it is reasonable to 
assume that factors involved in cell cycle regulation may have important roles in the 
adipocyte differentiation process.  We have proposed that HuR may be influencing 
mitotic clonal expansion.  Suppression of HuR lead to lower protein levels of cyclins A, 
E, and D1 and a lag in the expression pattern compared to the controls.  The data are 
similar to those reported by Dormoy-Raclet et al. (15), a study in which depletion of 
HuR in HeLa cells led to attenuation of the movement through the cell cycle.  In 
addition to the cyclins, HuR suppression led to decreased protein levels of both p53 and 
p21.  These two factors are expressed at significant levels and have been demonstrated 
to be required for the differentiation process (40).  The p53 mRNA has a HuR binding 
site in the 3’-UTR and the interaction is thought to control translational efficiency, thus, 
loss of HuR led to decreased p53.  It appears likely that the decrease in p21 protein may 
be mediated by loss of p53 and thus decreased transactivation of the p21 gene.  Taken 
together down-regulation of cyclins, p53 and p21 expression most certainly leads to a 
decreased ability of the cells to undergo an effective mitotic clonal expansion efficiently.  
These observations are consistent with HuR playing a significant role in the onset of 
adipogenesis.  
 C/EBPβ is essential for the acquisition of the adipose phenotype and its 
expression occurs early in the differentiation process, for that reason, we had selected 
C/EBPβ as a potential target of HuR.  We have verified that HuR binds to C/EBPβ 
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mRNA 3’untranslated region forming an mRNP that translocates to the cytosol upon 
stimulation with differentiation inducers.  Our original hypothesis suggested that HuR 
binding to the C/EBPβ mRNA was essential for the translocation of the message from 
the nucleus to the cytosol.  However, our data proved quite the opposite as the message 
was demonstrated to translocate more effectively without the interaction with HuR.  
This led to increased cytosolic C/EBPβ mRNA and protein resulting in overexpression 
of the C/EBPβ downstream target, C/EBPα and an enhanced acquisition of the 
adipocyte phenotype.  These observations are consistent with the formation of a HuR-
C/EBPβ mRNA complex controlling the rate at which C/EBPβ mRNA is available in 
the cytosol for protein synthesis.  Taken together these data support a function of HuR 
in the post-transcriptional regulation of C/EBPβ mRNA metabolism during early stages 
of adipogenesis.  
 Examination for potential mRNA ligands of HuR using an RNA 
Immunoprecipitation–Chip assay allowed the identification of a discrete subset of 
mRNAs associated with HuR.  Notably, the population of mRNPs changed markedly 
during the initial 30 minutes of the adipocyte differentiation program.  A unique subset 
of 193 mRNA targets found only at 0 time and a unique 45 mRNA targets at 30 min post 
induction of differentiation are genes that encode for transcription factors, as well as 
other proteins involved in transcriptional regulation, RNA binding proteins, proteins 
involved in apoptosis, and cell cycle proteins.  Similarly, Tenenbaum et al. identified 
targets of HuB (HuR-related protein) during neuronal differentiation of P19 cells using 
RIP-ChIP technology (82).  This revealed the existence of subsets of mRNAs that were 
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coordinately regulated at the post-transcriptional level.  This functional approach to 
genomics has been termed ―ribonomics"  and designed to elucidate functional 
connections between groups of genes that are expressed concurrently during biological 
processes (82).  The primary hypothesis of this model is that mRNAs are organized into 
groups sharing common functions and structural features.  It is conceivable that a 
common RNA-binding protein could thus effectively regulate these linked mRNA 
subpopulations during cellular processes such as proliferation, differentiation, and the 
stress response.  Keene et al. and Tenenbaum et al. (44, 82) recently proposed that 
mRNA-protein associations share equivalent characteristics to that of operons.  The 
present investigation provides evidence that HuR coordinately regulates a subset of 
genes with critical functions maintaining preadipocyte potential and during early stages 
in adipogenesis, thereby lending support to the post-transcriptional operon model.   
 This analysis also revealed a novel HuR ligand mRNA at the 30min time point, 
Zfp206, a poly-zinc finger transcription factor whose expression has only been described 
in embryonic stem cells.  Our data indicated that Zfp206 protein is transiently expressed 
during the differentiation program and its expression is down-regulated as the cells 
enter a terminal differentiated state.  Also documented was a 32 kDa splice variant, 
Zscan10.201, which lacks the zinc finger domain and is transiently expressed when 
Zfp206 is down-regulated at day 3.  These observations as well as the proposed 
regulatory role assigned to Zfp206 in ES cells have led us to hypothesize that expression 
of Zfp206 is essential for maintenance of the adipogenic differentiation potential.  Zfp206 
may mediate maintenance directly or by control of specific genes that in turn control 
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differentiation potential.  The suggestion of uncovering a regulatory gene for the 
maintenance of the preadipocyte state opens up the possibilities to novel therapeutics 
targeting obesity. 
  In this study, we provide evidence that expression of C/EBPβ, Cyclins A, E, D, 
p53, p21, and Zfp206 during adipocyte differentiation is subject to regulation by direct 
or indirect interaction with the RNA-binding protein HuR.  Our findings support a role 
for HuR in coordinately regulating the expression of several genes that play pivotal 
roles in the maintenance or the establishment of the adipocyte phenotype.  Previous 
studies have demonstrated a role for HuR in coordinating the expression of a set of 
genes involved in the same biological process.  For example, HuR influenced the 
expression of both cyclin A and cyclin B1 during the cell division cycle by 
proportionally stabilizing their respective mRNAs during the proliferative phases (91).  
Likewise, cellular response to stresses such as exposure to UV light caused coordinate 
changes in the stability of several stress-response genes, like the p21 (92).   
 Based on the accumulated data we have confirmed that HuR plays an important 
role in the metabolism of several key mRNA ligands during the induction of 
differentiation of the 3T3-L1 preadipocyte cell line.  Moreover, we have described a 
novel mRNA ligand for HuR that may be responsible for the maintenance of the 
differentiation potential of the preadipocytes.  
 Among the metabolic disorders obesity is the most common and significantly 
increases the risk of the developing type II diabetes. The long-term objectives are to 
understand the molecular mechanisms that regulate the differentiation of preadipocytes 
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into fully functional adipocytes. Thus, this brings us one step closer to understanding 
the relationship between excess adipose tissue and the development of insulin 
resistance and diabetes. Our recent studies have contributed significantly to the 
elucidation of the network of control points in the regulation of adipogenesis; control 
points that could be potential drug targets.  Further investigation into the role that HuR 
plays in regulating genes involved in adipogenesis may provide novel insights into the 
treatment and diagnosis of obesity and diabetes. 
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Figure 26 – Expression of adipogenic transcription factors during differentiation of 
3T3-L1 preadipocytes. The degree of expression is indicated by the intensity of the 
green zones on the horizontal band corresponding to each transcription factor. 
Transcription factors are arranged according to relationship with HuR. The 
differentiation protocol is as described. (adapted from Mandrup and Lane (53)) 
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